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1.1 NOVEL DRUG DELIVERY SYSTEMS (NDDS) 1 
The basic goal of novel drug delivery system is to achieve a steady state blood 
or tissue level that is therapeutically effective and non toxic for an extended period of 
time. 
 
Conventional drug delivery involves the formulation of the drug into a suitable 
form, such as compressed tablet for oral administration or a solution for IV 
administration. These dosage forms have been found to have serious limitations in 
terms of higher doses required lower effectiveness, toxicity & adverse effects. 
 
          NDDS are being developed rapidly, so as to overcome the limitations of 
conventional drug delivery. 
 
          Therapeutic Benefits of Novel drug delivery systems over conventional dosage 
forms 
 Increased efficacy of the drug. 
 Site specific delivery. 
 Decreased toxicity / side effects. 
 Increased convenience. 
 Shorter hospitalization. 
 Viable treatments for previously incurable diseases. 
 Potential for prophylactic application. 
 Lower health care costs, both short & long term. 
 Better patient compliance. 
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The reasons for intense interest in NDDS is due to 
 The recognition of the possibility of repeating successful drugs by 
applying concepts and techniques of controlled release drug delivery 
systems, coupled with the increasing expense in bringing new drug entities 
to market has encouraged the development of NDDS. 
 NDDS are needed to deliver the novel, genetically engineered 
pharmaceuticals, i.e. Peptides and proteins to their sites of action without 
incurring significant immunogenic or biological inactivation. 
 Treating enzyme deficient diseases & cancer therapies can be improved by 
better drug targeting. 
 Therapeutics & safety drug administered by conventional route can be 
improved by more precise spatial and temporal placement within the body, 
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1.2 TARGETING DRUG DELIVERY 
Targeted drug delivery may be achieved by using carrier systems, where 
reliance is placed on exploiting both, intrinsic pathway(s) that these carriers follow, 
and the bioprotection that they can offer to drugs during transit through the body. The 
various approaches of vectoring the drug to the target site can be broadly classified as 
 
 Passive targeting 
 Inverse targeting 
 Active targeting (Ligand mediated targeting and Physical targeting) 
 Dual targeting 
 Double targeting 
 Combination targeting 
 
1.2.1.    Passive Targeting 
It is a sort of passive process that utilizes the natural course of (attributed to 
inherent characteristics) biodistribution of the carrier system, through which, it 
eventually accumulate in the organ compartment(s) of body. The ability of some 
colloids to be taken up by the RES especially in liver and spleen has made them as 
ideal vectors for passive hepatic targeting of drugs to these compartments. Passive 
capture of colloidal carriers by macrophages offer therapeutic opportunities for the 
delivery of anti-infectives for disease conditions that involve macrophage cells of the 
reticuloendothelial system (RES) e.g., leishmaniasis, brucellosis and candidiasis. 
Delivery into lysosomal compartment can also be affected for the treatment of certain 
lysosomal storage diseases, macrophage neoplasms and macrophage activation. 
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1.2.2.    Inverse Targeting 
It is essentially based on successful attempts to circumvent and avoid passive 
uptake of colloidal carriers by reticuloendothelial system (RES). This effectively leads 
to the reversion of biodistribution trend of the carrier and hence the process is referred 
to as inverse targeting. One strategy applied to achieve inverse targeting is to suppress 
the function of RES by a pre-injection of a large amount of blank colloidal carriers or 
macromolecules like dextran sulphate.  This approach leads to RES blockade and as a 
consequence impairment of host defense system. Alternative strategies include 
modification of the size, surface charge, composition, surface rigidity and 
hydrophilicity of carriers for desirable biofate. Recently available literature suggests 
modification of the surface by imparting distinctive hydrophilicity to the carrier 
Enhanced 
Permeability & 
Retention Effect 
Passive   Active Ligand 
receptor 
  Organ conditions    Biological pairs     
Drug Targeting 
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particles, as an effective mode of targeting of drug(s) to non-RES organs. 
Phospholipid Microspheres emulsified with Poloxamer 338 showed the’ lowest RES 
uptake in mouse peritoneal macrophages in vitro. Poloxamine 908 is another 
hydrophilic nonionic surfactant, which diverts normal RES uptake of coated emulsion 
and coated nanoparticles (polystyrene micro sphere to inflammatory sites in rabbits. 
 
Inverse targeting of drugs to the other than RES rich organs by coating the 
lipid Micro emulsion (LM) with Poloxamer 308.   It   has   been   suggested   that   
surface hydrophilicity may reduce or even eliminate the adhesion of opsonin 
materials/HDL on to the surface of LM, Which is believed to be an essential step in 
the process of phagocytosis responsible for ultimate uptake of LM by RES system. 
 
1.2.3.   Active Targeting 
Active targeting exploits modification or manipulation of drug carriers to redefine 
its biofate. The natural distribution partum of the drug carrier composites is enhanced 
using chemical, biological and physical means, so that it approaches and identified by 
particular biosites. The facilitation of the binding of the drug-carrier to target cells through 
the use of ligands or engineered homing devices to increase receptor mediated (or in some 
cases receptor independent but epitope based) localization of the drug and target specific 
delivery of drug(s) is referred to as active targeting. 
 
The targeting approach can further be classified it into three different levels of 
targeting, first order targeting (organ compartmentalization), second order targeting 
(cellular targeting) and third order targeting (intracellular targeting). 
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♦ First order targeting: 
It refers to restricted distribution of the drug-carrier system to the capillary bed 
of a predetermined target site, organ or tissue. Compartmental targeting in lymphatic, 
peritoneal cavity, plural cavity, cerebral ventricles, lungs, joints, eyes, etc., represents 
first order targeting. 
 
♦ Second order targeting: 
The selective delivery of drugs to a specific cell type such as tumor cells and 
not to the normal cells is referred as second order drug targeting. The selective drug 
delivery to the Kupffer cells in the liver exemplifies this approach. 
 
♦ Third order targeting: 
The third order targeting is defined as drug delivery specifically to the 
intracellular site of target cells. An example of third order targeting is the receptor 
based ligand-mediated entry of a drug complex into a cell by endocytosis, lysosomal 
degradation of earner followed by release of drug intracellularly. 
 
1.2.4.    Ligand Mediated Targeting 
             Targeting components, which have been studied and exploited are pilot 
molecules themselves (bioconjugates) or anchored as ligands on some delivery 
vehicle (drug-carrier system). All the carrier systems, explored so far, in general, are 
colloidal in nature. They can be specifically functionalized using various biologically 
relevant molecular   ligands   including   antibodies,   polypeptides,   and 
oligosaccharides carbohydrates), viral proteins and fusogenic residues. The ligands 
afford specific avidity to drug carrier. The engineered carrier constructs selectively 
deliver the drugs to the cell or group of cells generally referred to as target. The 
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cascade of events involved in ligand negotiated specific drug delivery is termed as 
ligand driven receptor mediated targeting. 
 
1.2.5.   Combination Targeting 
             These targeting systems are equipped with carriers, polymers and homing 
devices of molecular specificity that could provide a direct approach to target site. 
Modification of proteins and peptides with the natural polymers, such as 
polysaccharides containing natural polymers, such as polysaccharides, or their tissues 
within the vasculature.  
 
1.2.6. MERITS OF TARGETED DRUG DELIVERY SYSTEM (TDDS) 2 
♦ Targeted drug delivery system provides a reduction in drug blood level          
fluctuation. It provides a control in the rate of drug release in case of controlled drug 
delivery system i.e. the "Peaks and valleys" of drug in blood or serum levels are 
eliminated. 
 
♦ There is a reduction in dosing frequency i.e. the rate-controlled products deliver 
more than a single dose of medication and then are taken less often than conventional 
forms. 
 
♦ Enhanced patient convenience and compliance with less frequency of dose 
administration, the patient is less apt to neglect take mg, a dose. There is a\so greater 
patient convenience with day time and night time medication, and acute or chronic 
illness. 
 
♦ Reduction is adverse side effects. Because there are seldom drug blood level peaks 
above the drugs therapeutics range, and into the toxic range, adverse side effects are 
less frequently encountered. 
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♦ Reduction in health care costs (i.e.) economy. Although the initial cost of rate-
controlled drug delivery form, the average cost of treatment over extended time period 
may be less with less frequency of dosing enhanced therapeutic benefit and reduced 
side effects, the time required for health care personal to dispense, administer and 
monitor patient is reduced. 
 
♦ The major merit of CDDS is that the duration of action can be extended for days or 
months sometimes up to one year. 
 
1.2.7. LIMITS OF TARGETED DRUG DELIVERY SYSTEM (TDDS) 
♦ Certain other TDDS shows poor site specificity e.g., Microsphere. 
♦ Targeted drugs delivery system as liposomes, resealed erythrocytes and platelets 
suffer serious stability problem. 
♦ If the particle size of TDDS is high, they may be rapidly cleared by 
reticuloendothelial system (RES). 
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1.3. NANOPARTICLES 2, 3 
 Nanoparticles are sub-Nano sized colloidal structures composed of synthetic 
or semi synthetic polymers. Nanoparticles are solid colloidal particles ranging in size 
10 nm to 1000 nm (1µm). They are classified into two groups: 
 
 Nanosphere defined as solid core spherical particulates, which are nano metric 
in size. They contain drug embedded within or adsorbed on to surface.  
 Nanocapsules are vesicular system in which drug is essentially encapsulated 
within the central volume surrounded by an embryonic continuous polymeric 
sheath. 
 
Nanoprticles (NPs) based drug delivery system has considerable potential for 
the treatment of Cancer. The importance technological advantages of NPs used has 
drug carrier are high stability, high carrier capacity, feasibility of incorporation of 
both hydrophilic and hydrophobic substances and feasibility of variable routes of 
administration including oral application, parenteral  administration  and inhalation. 
  
 There has been considerable interest in developing biodegradable nanospheres 
as effective drug delivery system. The controlled release of pharmacologically active 
agents to the specific site of action at the therapeutically optimal rate and dose 
regimen has been a major goal in designing such devices. Various polymers have 
been explored as sustained release and protective carrier of drugs to a target site and 
thus increase the therapeutic benefit, while minimizing side effects. Among these 
polymers, Eudragit have tremendous interest due to their excellent biocompatibility 
and biodegradability several of formulations using these polymers have received 
world wide marketing approval. 4 
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 Synthetic biodegradable polymers have been increasingly used to deliver 
drugs, since they are free from most of the problems associated with the natural 
polymers. The natural polymers are limited due to their higher cost and questionable 
purity. Biodegradable polymers from natural or synthetic origin are degraded either 
enzymatically or non- enzymatically or both produce biocompatible, toxicologically 
safe by-products which are further eliminated by the normal metabolic pathways. 
 
1.3.1 Advantage of nanoparticles 2 
 Enhancement of therapeutic effectiveness of the drug i.e. the over all 
pharmacological response per unit dose in increased. 
 Toxicity and adverse drug reactions are reduced to a possible extent e.g. 
polymethacrylic nanoparticles for targeting anticancer drug Doxorubicin to 
reduce liver toxicity. 
 Nanoparticles posses’ better stability as compared to liposomes which makes 
it more important for many modes of targeting.  
 Nanoparticles formulated as amorphous spheres offer solubility than standard 
crystalline formulations, thus improving the poor aqueous solubility of the 
drug and hence the bioavailability.  
 The methods of preparation are simple, easier and reproducible.  
 A high degree of patient compliance can be achieved. 
 Wide range of polymer can be used depending on the nature, of the drug and 
usage i.e. biodegradable polymer for shorter periods, and non- biodegradable 
for longer periods.  
 It can easily pass through syringe needle and exhibit good rheological 
properties.  
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1.3.2. Preparation techniques of nanoparticles 5, 6 
Polymer precipitation methods.  
 Emulsification – solvent evaporation  
 Solvent displacement (Nanoprecipitation) 
 Salting out  
 
1.3.2.1. Emulsification – solvent evaporation method 
  The method has two alternatives depending on the nature of the drug to be 
entrapped within the nanospheres: the simple emulsion (w/o) and the double emulsion 
(w/o/w) techniques. In the first, this is used for the encapsulation of hydrophobic 
drugs. The polymer and the drug are dissolved in the volatile organic solvent 
immiscible with water, such as dichloromethane or emulsified under intense shear 
using homogenization, microfluidisaiton or probe sonication into an aqueous phase 
contains appropriate amounts of a surfactant 9e.g. sodium cholate or PVA). The 
organic solvent is allowed to nanoparticles formed are usually collected by 
centrifugation redispersed in distilled water and freeze dried in the second method, 
which used for the encapsulation of hydrophilic drug and proteins, the drug is 
dissolved in a small volume of an aqueous phase and this is emulsified in an organic 
phase containing the polymer. The w/o emulsion formed is then dispersed in a larger 
volume of an aqueous phase to form the double w/o/w/ emulsion. The remaining steps 
of the preparation are the same as in the simple emulsion method.  
 
Advantages: 
 The use of non- highly –toxic solvents (i.e. ethyl acetate). 
 Additives can be used for nanoparticle size reduction. 
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 Suitable for hydrophilic (double emulsions) and hydrophobic active 
components.  
 The solvent is removed by evaporation (energy consumption), but the process 
time for solvent removal is reduced (special with fast evaporation with 
vacuum). 
 
Disadvantages: 
 The addition of active component affects the final size of nanoparticles. 
 High consumption of energy by the necessity of high shear stress (i.e. 
sonication). 
 The major drawbacks of this method are the use of relatively toxic organic 
solvents dichloromethane and chloroform belong to class 2 in the ICH 
guidelines for residual solvents and the application of intense shear. Both the 
presence of the organic solvent and the application of intense shear forces may 
cause degradation of labile drugs, such as proteins.  
 
1.3.2.2. Solvent displacement method 7 
 The polymer and the drug are dissolved in the organic solvent miscible with 
water (e.g. acetone) the organic phase is slowly transferred to an aqueous phase 
containing a surfactant (e.g. PVA or poloxamer 188) under mild stirring. A submicron 
o/w emulsion is spontaneously formed drug to immediate reduction of the interfacial 
tension with rapid diffusion of acetone into the aqueous phase (the Marangoni effect). 
Following acetone diffusion, the nanospheres are formed by aggregation of polymer 
and drug. The organic solvent is removed by evaporation and the nanosphere 
suspension is concentrated under reduced pressure, purified by centrifugation or 
dialysis (removal of non- entrapped drug and excess surfactant) and freeze dried the 
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presence of surfactant) facilitate their sedimentation. The term nano precipitation and 
solvent diffusion have also been used to describe solvent displacement techniques.  
 
 To improve the encapsulation of water-soluble drugs changed the dispersing 
medium from an aqueous solution to a medium chain triglyceride (span 80) in the 
polymer phase. Another drawback of this method is that many drugs are not well 
soluble in the semi polar solvents, such as acetone or alcohol. To improve the 
solubility and entrapment of certain drugs a mixture of acetone with dichloromethane 
was used instead of acetone alone. 
 
Advantage: 
 The use of non – highly –toxic solvents (acetone). 
 Reduced energy consumption because it only required regular stirring. The 
process does not require high stress shear. (I.e. sonication or microfluization).  
 Additives can be used for nanoparticle size reduction. 
 
Disadvantages: 
 The solvent is removed by evaporation (time consuming). 
 The main draw back is the requirement for drugs to be highly soluble in polar 
solvents (acetone, ethyl acetate) and slightly soluble in water to minimize 
losses during solvent diffusion.  
 Nanoparticle size is very much affected by the polymer concentration, higher 
nanoparticle sizes are obtained at higher polymer concentrations.  
 
1.3.2.3. Salting out method 
 In the salting out method, the polymer and the drug are dissolved in a water- 
miscible solvent (e.g. acetone or tetrahydrofuran) and the solution is emulsified under 
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vigorous mechanical stirring in an aqueous gel containing the salting out agent and a 
colloidal stabilizer (e.g. to enhance the with a sufficient volume of water to enhance 
the diffusion of acetone in to aqueous phase, thus inducing the formation of 
nanospheres salting as salting electrolytes, such a sucrose. 
 
 The method is available for the preparation of polymeric nanosphere and 
nanocapsules degradation and drug dissolution or leakage, which are very likely to 
occur if the nanospheres are stored as aqueous dispersions.  
 
 To prevent nanosphere aggregation and retain nanosphere redispersibility after 
freeze-drying, a suitable cryoprotectant such as trehalose or sucrose has to be added in 
the nanosphere dispersion lyophilization. 
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Summary of the different methods to prepare nanospheres and the nanocapsules 
from polymer. 8 
By increasing the concentration of the nanopraticles suspension at a very low 
temperature improved the lyoprotective effect of trehalose. They also reported that 
most of the lyoprotected nanosphere remained stable for at least 12 weeks when 
stored at +40C and -250C under dry argon. 
 
Advantages: 
 Reduced emerge consumption because it only requires normal stirring. The 
process does not require high stress shear (i.e. sonication or microfluidization).  
 Low time- consuming process. 
 Suitable for hydrophobic components because the salting out agent is water 
soluble.  
 
Disadvantages: 
 The use of not highly toxic, but explosive solvents (i.e. acetone). 
 The main drawback is the requirement of a purification step for salting out 
agent elimination, which is the in higher amount (at least three times more 
amount of salting out than polymer). 
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1.4. NANOPARTICLES IN OCULAR DRUG DELIVERY 9 
1.4.1. Conventional Dosage Forms and Restrictions 
 The main objective in ocular therapeutics is to provide and maintain adequate 
concentration of the drug at the site of action. Most ocular diseases are treated with 
topical applications of solutions administered as eye drops. The major deficiencies of 
this conventional dosage form include poor ocular drug bioavailability, pulse drug 
entry, systemic exposure due to the nasolacrimal duct drainage, and poor entrance to 
the posterior segments of the eye due to the lens diaphragm. 
 
 Poor ocular drug bioavailability is the result of ocular anatomical and 
physiological constrains, which protect the eye and maintain visual functions. After 
instillation of an ophthalmic drug, most of it is rapidly eliminated from the pre corneal 
area due to drainage by the nasolacrimal duct, blinking and dilution by the tear 
turnover (approximately 1µl/min). it has been determined that as much as 90% of the 
50ml dose administered as eye drops is cleared within 2 minutes and only 1-5% of the 
administered dose permeates to the eye. Furthermore, the cornea is a highly selective 
barrier with five different layers that exclude compounds from the eye. The main 
corneal barriers are the (i) lipophilic epithelium layers (50µm) with its tight junctions 
and high turnover of one cell layer per day and (ii) the hydrophilic stroma (450 µm) 
which represents a rate limiting barrier for absorption of lipophillic drugs. The 
conjuctival uptake of topically applied drugs is typically in an order of magnitude 
greater than the corneal uptake due to the relative leakiness of the membrane, the rich 
blood flow, and the large surface area. Most drugs however are rapidly removed by 
systemic uptake through the vessels embedded in that tissue before diffusion to the 
intraocular tissues. Enzymatic metabolism may also account for further loss which 
can occur in the precorneal space or in the cornea. Therefore, high administration 
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frequency and large doses of drug are required, resulting with fluctuations in ocular 
drug concentrations and local / systemic side effects. These systemic side effects after 
topical administration, mainly due to the nasolacrimal drainage, can cause severe 
systemic toxicity when using potent drugs such as timolol. 
 
 Systemically administered drugs have poor access to the eye because of the 
blood-ocular barrier, which physiologically separates the eye from the rest of the body 
by epithelial and endothelial components whose tight junctions limit transport from 
blood vessels to the eye. The barrier is comprised of two systems; (i) the blood-
aqueous barrier, which prevents drugs from entering the aqueous humor, and (ii) the 
blood-retinal barrier, which prevents drugs from entering into the extra vascular space 
o retina and into the vitreous body. Subconjuctival and intravitreal injections of drugs 
are also applied clinically, generating elevated intraocular concentrations with 
minimal systemic effects. These methods, however, are painful, inconvenient, and 
associated with severe complications such as perforation of the globe and scarring of 
the conjunctiva. 
 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
19
1.4.2. Ocular Pharmacokinetics: 10 
The main routes of drug administration and elimination from the eye have 
been shown schematically in Fig. 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig1. Schematic presentation of the ocular structure with the routes of drug 
kinetics illustrated. The numbers refer to following processes: 1) transcorneal 
permeation from the lacrimal fluid into the anterior chamber, 2) non-corneal drug 
permeation across the conjunctiva and sclera into the anterior uvea, 3) drug 
distribution from the blood stream via blood-aqueous barrier into the anterior 
chamber, 4) elimination of drug from the anterior chamber by the aqueous humor 
turnover to the trabecular meshwork and Sclemm's canal, 5) drug elimination from the 
aqueous humor into the systemic circulation across the blood-aqueous barrier, 6) drug 
distribution from the blood into the posterior eye across the blood-retina barrier, 7) 
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intravitreal drug administration, 8) drug elimination from the vitreous via posterior 
route across the blood-retina barrier, and 9) drug elimination from the vitreous via 
anterior route to the posterior chamber. 
 
1.4.3. The Barriers 
1.4.3.1. DRUG LOSS FROM THE OCULAR SURFACE 
After instillation, the flow of lacrimal fluid removes instilled compounds from 
the surface of the eye. Even though the lacrimal turnover rate is only about 1 µl/min 
the excess volume of the instilled fluid is flown to the nasolacrimal duct rapidly in a 
couple of minutes. Another source of non-productive drug removal is its systemic 
absorption instead of ocular absorption. Systemic absorption may take place either 
directly from the conjunctival sac via local blood capillaries or after the solution flow 
to the nasal cavity. Anyway, most of small molecular weight drug dose is absorbed 
into systemic circulation rapidly in few minutes. This contrasts the low ocular 
bioavailability of less than 5%. Drug absorption into the systemic circulation 
decreases the drug concentration in lacrimal fluid extensively. Therefore, constant 
drug release from solid delivery system to the tear fluid may lead only to ocular 
bioavailability of about 10%, since most of the drug is cleared by the local systemic 
absorption anyway.  
 
1.4.3.2. LACRIMAL FLUID-EYE BARRIERS 
Corneal epithelium limits drug absorption from the lacrimal fluid into the eye. 
The corneal barrier is formed upon maturation of the epithelial cells. They migrate 
from the limbal region towards the center of the cornea and to the apical surface. The 
most apical corneal epithelial cells form tight junctions that limit the Para cellular 
drug permeation. Therefore, lipophilic drugs have typically at least an order of 
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magnitude higher permeability in the cornea than the hydrophilic drugs. Despite the 
tightness of the corneal epithelial layer, transcorneal permeation is the main route of 
drug entrance from the lacrimal fluid to the aqueous humor    (Fig. 1). In general, the 
conjunctiva is leakier epithelium than the cornea and its surface area is also nearly 20 
times greater than that of the cornea. Drug absorption across the bulbar conjunctiva 
has gained increasing attention recently, since conjunctiva is also fairly permeable to 
the hydrophilic and large molecules. Therefore, it may serve as a route of absorption 
for larger bio-organic compounds such as proteins and peptides. Clinically used drugs 
are generally small and fairly lipophilic. Thus, the corneal route is currently 
dominating. In both membranes, cornea and conjunctiva, principles of passive 
diffusion have been extensively investigated, but the role of active transporters is only 
sparsely studied.  
 
1.4.3.3. BLOOD-OCULAR BARRIERS 
The eye is protected from the xenobiotics in the blood stream by blood-ocular 
barriers. These barriers have two parts: blood-aqueous barrier and blood-retina barrier 
(Fig. 1). The anterior blood-eye barrier is composed of the endothelial cells in the 
uvea. This barrier prevents the access of plasma albumin into the aqueous humor, and 
limits also the access of hydrophilic drugs from plasma into the aqueous humor. 
Inflammation may disrupt the integrity of this barrier causing the unlimited drug 
distribution to the anterior chamber. In fact, the permeability of this barrier is poorly 
characterized. The posterior barrier between blood stream and eye is comprised of 
retinal pigment epithelium (RPE) and the tight walls of retinal capillaries. Unlike 
retinal capillaries the vasculature of the choroid has extensive blood flow and leaky 
walls. Drugs easily gain access to the choroidal extra vascular space, but thereafter 
distribution into the retina is limited by the RPE and retinal endothelia. Despite its 
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high blood flow the choroidal blood flow constitutes only a minor fraction of the 
entire blood flow in the body. Therefore, without specific targeting systems only a 
minute fraction of the intravenous or oral drug dose gains access to the retina and 
choroid. Unlike blood brain barrier, the blood-eye barriers have not been 
characterized in terms of drug transporter and metabolic enzyme expression. From the 
pharmacokinetic perspective plenty of basic research is needed before the nature of 
blood-eye barriers is understood. 
 
1.4.4. Early Attempts to Enhance Ocular Bioavailability: 11 
Initial attempts to overcome the poor bioavailability of topically instilled drugs 
typically involved the use of ointments based on mixtures of white petrolatum and 
mineral oils and suspensions. Ointments ensure superior drug bioavailability by 
increasing the contact time with the eye, minimizing the dilution by tears, and 
resisting nasolacrymal drainage. Because these vehicles have the major disadvantage 
of providing blurred vision, they are nowadays mainly used for either nighttime 
administration or for treatment on the outside and edges of the eyelids. Use of 
suspensions as ophthalmic delivery systems relies on the assumption that particles 
may persist in the conjunctival sac. The efficiency of suspensions has shown high 
variability, which occurred as a result of inadequate dosing, probably mainly due to 
the lack of patients compliance in adequately shaking the suspension before 
administration. These disadvantages have led to other approaches being investigated. 
One of the common methods to optimize prolonged precorneal residence time is to 
use hydro gels, liposomes, and micro- and nanocarrier systems. In comparison with 
traditional formulations, these systems have the advantages of increased contact time, 
prolonged drug release, reduction of systemic side effects, reduction of the number of 
applications, and better patient's compliance. 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
23
1.4.5. New Ocular Drug Delivery Systems: 9 
 Various attempts have been made to improve drug bioavailability by 
increasing both the retention of the drug in the pre-corneal area and the penetration of 
the drug through the cornea. In addition, patient compliance and comfort 
considerations in drug administration are important factors that may impact the drugs 
therapeutic efficacy. 
  
 These attempts can be divided into two main categories: bioavailability 
improvement and controlled- release drug delivery. The first category includes gels, 
viscosity enhancers such as Carboxy Methyl Cellulose, Polyvinyl alcohol and 
Carbomers, penetration enhancers, pro-drugs and liposomes. The second category 
includes various types of inserts and nanoparticles.  
 
 The effect of gels and viscosity enhancers on drug bioavailability was found to 
be a minimal, and vision blurring limits their chances of becoming popular dosage 
forms, although marketed products are available. Penetration enhancers caused ocular 
irritation and toxicity, thus no commercial product was developed, and pro-drugs are 
difficult to design and develop as evidenced by the fact that probably only one 
ophthalmic pro-drug has been commercialized. Also, inserts are not very popular as 
drug delivery systems due to patient discomfort and difficulty in administering and 
maintaining, especially by elderly patients. Liposomes have been extensively 
investigated as ocular drug delivery vehicles for over a decade because they offer 
potential benefits of controlled release and protection from metabolic process. 
However, many problems are associated with liposomes administration to the eye 
such as; toxicity, irritability, low drug loading, manufacturing difficulties for sterile 
preparation and inadequate aqueous stability. 
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 To address the above stated problems, micro and nanotechnology involving 
drug-loaded polymer particles have been proposed as ophthalmic drug delivery 
techniques providing sustained release of drug targeted to the ocular tissues.  
 
1.5. CATARACT 12 
Any opacity in the lens either developmental or acquired either in its capsule 
or substance of lens is called cataract.  
   
Forty year and above; sexes are equally affected common causes of blindness 
in the population; 80% of blindness is caused by cataract. 
 
1.5.1. Aetiopathogenesis of Cataract 
 Exact cause of cataract is unknown. There is a derangement of metabolism of 
lens, like interference in nutrition as occurs in local eye disease, penetrating trauma 
which might injure the lens and cause water accumulation leading to cataract. But the 
common cataract is senile cortical cataract, which occur commonly after 50-60 years 
of ago the cause, of which is not known. 
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1.5.2. Senile Cataract 
 Lens fibres are constantly formed from anterior lens capsule and the fibres are 
arranged regularly in the lens. The older fibres are pushed to centre and condensed to 
form nucleus. The peripheral or cortical fibres undergo lamellar separation in which 
fluid droplets appear in between lens fibres. This leads to disturbance in lens 
metabolism and coagulation of protein of lens fibres. This leads to wedge shaped grey 
areas as opacity in the cortex. This stage is called immature cataract. 
 
 
Immature Cataract 
Occur initially in the lower and nasal quadrants of lens. Gradually more and 
more opacity formed between nucleus and cortex and lens appears grey in colour 
gradually more and more opacity formed and leads to total opacity of lens and colour 
become grayish-white or purple or pearly-white colour. This stage is called mature 
cataract. 
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.  
Mature Cataract 
 During accumulation of water droplets, sudden accumulation of more water 
gets clogged and whole lens becomes intumescent; swollen and pushes the iris 
diaphragm forward and cause secondary glaucoma in few cases rarely. In senile 
cataract some times the opacity strats in the central portion of immediately beneath 
the posterior capsule and later involve the entire cortex and called posterior sub 
scapular cataract. 
 
Posterior sub scapular Cataract 
 When the cortical mature cataract becomes hyper mature if not treated. The 
cortical lens matter is liquefied and the nucleus sinks down into capsule and this stage 
is called Morgagnian cataract. 
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Morgagnian Cataract 
1.5.3. Senile Nuclear Cataract 
 The central nucleus is sclerosed and cortical fibres remain transparent. Then 
nucleus becomes cloudy and cloudiness spreads to cortex also. There is formation of 
brown pigment and deposition yellow-pigmented lipoprotein. 
 
1.5.4. Senile Cortical Hypermature Cataract or Shrunken Cataract 
 In this variety cortical fibres become sclerosed, hardened, dry and flattened 
leading to the tremulousness of lens, and deep chamber. 
 
1.5.5. Symptoms of Cataract 
 Black spots in the field of vision 
 Dashing of light while driving in night 
 Polyopia 
 Haloes around the light 
 Detective vision 
 Improvement in near vision (due to lenticular myopia) 
 Repeated changing of glasses 
 Loss of vision (gradual onset) 
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1.5.6. Signs of Cataract  
1. 50 years above common, 40 to 50 years relatively uncommon 
2. Both sexes are equally affected 
3. Grayish opacity in the papillary area. 
4. Iris shadow – when light is thrown at the side of eye iris casts a shadow over 
pupil in the area between lens opacity and clear lens-in immature cataract. 
5. White or grayish-white opacity in papillary area (leucocorea) in mature  
 
1.6. POLYMERS FOR DRUG DELIVERY 
 The choice of appropriate polymer, particle size, and manufacturing process 
will primarily depend on the bioacceptabiliy of the polymer, 
1.6.1. Characteristics of Ideal polymer system: 
An ideal polymer system should possess the following characteristics: 
1. It should be inert and compatible with the environment. 
2. It should be non-toxic. 
3. It should be easily administered. 
4. It should be easy and inexpensive to fabricate. 
5. It should have good mechanical strength. 
Polymers have been classified broadly as, 
¾  Natural polymers   – Albumin, Starch, Dextran, Gelatin, Fibrinogen, Chitosan. 
¾ Synthetic polymers – Polymethyl methacrylate, 
                                           Polymethyl methacrylate copolymers:    
 Polymethyl cyanoacrylate. 
 Polyacrylamide. 
 Polyacryl starch. 
 Polylactic acid. 
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Polymers are further classified on the basis of their interaction with water: 
¾ Non-biodegradable polymers 
They are inert in the environment of use and eliminated intact from the site of 
administration and are the limiting factor. 
Ex:  Polyethylene vinyl acetate (PVA), Polydimethyl siloxane (PDS) 
          Poly urethane (PEU), Ethyl cellulose (EC), Cellulose acetate (CA). 
¾ Hydro gels  
These type of polymers swell but do not dissolve when brought in contact with   
water. They are inert and remover intact from the site of administration. 
Ex:  Poly hydroxyl ethyl methacrylate (PHEMA), Cross linked polyvinyl 
alcohol (PVA) 
         Cross linked poly vinyl pyrrolidone (PVP), Polyacrylamide, Dextran. 
¾ Soluble polymers 
 They are moderate weight uncross-linked polymers that dissolve in water. 
  Ex:  Poly ethylene glycol (PEG), Hydroxy propyl methyl cellulose (HPMC). 
¾ Biodegradable polymers 
These slowly disappear from the site of administration into a chemical reaction 
like hydrolysis. 
Ex:  Polymethyacrylates (EUDRAGIT), Poly lactic acid (PLA). 
         
1.6.2. Drug release mechanisms for polymeric drug delivery devices: 
 Two broad categories of polymer systems have been studies. The reservoir 
device involves the encapsulation of a drug within a polymer shell, while the matrix 
device describes a system in which a drug is physically entrapped within a polymer 
network the drug will be released over time either by diffusion out the polymer matrix 
or by erosion (due to degradation) of the polymer or by a combination of two 
mechanisms.  
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REVIEW OF LITERATURE 
 
The pre-administration of Dexamethasone (DEX) has previously been shown 
to enhance the antitumor efficacy of chemotherapeutic agents. The delivery of anti-
inflammatory agents specifically to tumors via nanoparticle carriers is expected to 
promote the effectiveness of chemotherapeutic agents while avoiding systemic 
toxicities. The process for preparing solid lipid nanoparticles containing anti-
inflammatory agents using the nanotemplate engineering method was optimized. Due 
to the solubilization of DEX in the bulk aqueous phase, its more lipophilic palmitate 
ester was synthesized and incorporated in nanoparticles that included a pegylating 
agent, PEG 6000 mono-stearate, as part of the formulation. The stealth properties of 
these nanoparticles were demonstrated to be enhanced compared to latex particles by 
measuring the adsorption of radio iodinated IgG (185 µg vs. 6.7 µg IgG/mg NP). In 
addition, the uptake of 14C-labeled nanoparticles by murine macrophages was shown 
to decrease from 36.6% to 14.7% of the nanoparticles/mg cell protein as the amount 
of pegylating agent in the formulation increased from 0 to 4 mg/mL. The high loading 
values and low burst effect observed for this DEX palmitate-containing nanoparticles 
in addition to their stealth properties are expected to allow for the delivery of 
sufficient amounts of DEX to tumors to enhance the uptake of chemotherapeutic 
agents. 13 
 
Although eye drops are the most common form of ocular drugs, they have 
several limitations. Drug absorption into the eye is, in general, less than 5%, addition 
of preservatives is often necessary, and many drugs cannot be formulated as eye 
drops. Formulating ocular drugs as powder may solve these problems. The aim of this 
study was to investigate ocular irritation in rabbits following powder administration. 
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Timolol maleate (TM) powder was administered to pigmented lop rabbits. Both pure 
TM powder and freeze-dried with PVP-polymer (2.4% of mass) were tested in 1.0- 
and 0.1-mg doses. Additionally, 4 rabbits received 0.1 mg of the pure powder 3 times 
a day for 8 d. Redness of the bulbar conjunctiva and the amount of discharge was 
rated from photographs (0–3 points, randomized and masked evaluation). The 8-d 
experiment additionally included examination with a slit lamp and examination of 
heamatoxylin-eosin stained sections of eyes with light microscopy. No serious or 
irreversible signs of irritation were noted. Doses of 1.0 mg were more irritating than 
0.1-mg doses. There was no detectable difference in irritation between pure or freeze-
dried powder. Slit-lamp examination, surface photographs and histology showed a 
negligible difference between drug and control eyes following the 8-d experiment. 
The results suggest that 0.1 mg of timolol powder does not irritate the eye and that 
testing topical timolol powder in humans is feasible. 14 
 
The present paper concerns both the optimization of Dexamethasone (DXM) 
entrapment and its release from biodegradable poly (d, l-lactide-coglycolide) (PLGA) 
nanoparticles prepared by the solvent evaporation process. Since the addition of DXM 
induced the formation of drug crystals beside the nanoparticle suspension, the 
influence of several parameters on DXM encapsulation was investigated such as the 
type of organic solvent and polymer, the DXM initial mass, the evaporation rate of the 
solvent, the continuous phase saturation and the incorporation of a lipid in the 
polymer. Nanoparticle size and zeta potential were not modified in the presence of 
DXM and were respectively around 230 nm and −4mV. The highest drug loading was 
obtained using 100 mg PLGA 75:25 in a mixture of acetone-dichloromethane 1:1 
(v:v) and 10 mg of DXM. The drug was completely released from this optimized 
formulation after 4 h of incubation at 37 ◦C. Neither the evaporation rate of the 
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organic solvent, nor the aqueous phase saturation with salt or the incorporation of 
1mg 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) within the nanoparticles 
modified the encapsulation efficiency. Differential scanning calorimetric (DSC) and 
X-ray diffraction (XRD) demonstrated that the drug was molecularly dispersed within 
the nanoparticles whereas the non-encapsulated DXM crystallized. These results 
demonstrate the feasibility of encapsulating Dexamethasone and its subsequent 
delivery. 15 
 
The release of the anti-inflammatory agent Dexamethasone (DEX) from 
nanoparticles of poly (lactic-co-glycolic acid) (PLGA) embedded in alginate hydro 
gel (HG) matrices was investigated. DEX-loaded PLGA nanoparticles were prepared 
using a solvent evaporation technique and were characterized for size, drug loading, 
and in-vitro release. The cross linking density of the HG was studied and correlated 
with drug release kinetics. The amount of DEX loaded in the nanoparticles was 
estimated as _13 wt%. The typical particle size ranged from 400 to 600 nm. The in-
vitro release of DEX from NPs entrapped in the HG showed that 90% of the drug was 
released over 2 weeks. 16 
 
To assess the potential of Chitosan (CS) nanoparticles for ocular drug delivery 
by investigating their interaction with the ocular mucosa in vivo and also their toxicity 
in conjunctival cell cultures. Fluorescent (CS-fl) nanoparticles were prepared by 
ionotropic gelation. The stability of the particles in the presence of lysozyme was 
investigated by determining the size and their interaction with mucin, by measuring 
the viscosity of the mucin dispersion. The in vivo interaction of CS-fl nanoparticles 
with the rabbit cornea and conjunctiva was analyzed by spectrofluorimetry and 
confocal microscopy. Their potential toxicity was assessed in a human conjunctival 
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cell line by determining cell survival and viability. CS-fl nanoparticles were stable 
upon incubation with lysozyme and did not affect the viscosity of a mucin dispersion. 
In vivo studies showed that the amounts of CS-fl in cornea and conjunctiva were 
significantly higher for CS-fl nanoparticles than for a control CS-fl solution, these 
amounts being fairly constant for up to 24 h. Confocal studies suggest that 
nanoparticles penetrate into the corneal and conjunctival epithelia. Cell survival at 24 
h after incubation with CS nanoparticles was high and the viability of the recovered 
cells was near 100%.CS nanoparticles are promising vehicles for ocular drug 
Delivery. 17 
 
The aim of this study was to evaluate solid lipid nanoparticles (SLN) as 
carriers for topical ocular delivery of tobramycin (TOB). The SLN were in the 
colloidal size range (average diameter below 100 nm; polydispersity index below 0.2) 
and contained 2.5% TOB as ion-pair complex with hexadecyl phosphate. The 
preocular retention of SLN in rabbit eyes was tested using drug-free, fluorescent SLN 
(F-SLN): these were retained for longer times on the corneal surface and in the 
conjunctival sac when compared with an aqueous fluorescent solution. A suspension 
of TOB-loaded SLN (TOB-SLN) containing 0.3% w/v TOB was administered 
topically to rabbits, and the aqueous humour concentration of TOB were determined 
up to six hours. When compared with an equal dose of TOB administered by standard 
commercial eye drops, TOB-SLN produced a significantly higher TOB bioavailability 
in the aqueous humour. 18 
 
The objective of present study was to prepare positively charged 
ciprofloxacin-loaded nanoparticles providing a controlled release formulation. The 
particles were prepared by water-in-oil-in-water (w/o/w) emulsification and solvent 
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evaporation, followed by high-pressure homogenization. Two non-biodegradable 
positively charged polymers, Eudragit® RS100 and RL100, and the biodegradable 
polymer poly (lactic-co-glycolic acid) or PLGA were used alone or in combination, 
with varying ratios. The formulations were evaluated in terms of particle size and zeta 
potential. Differential scanning calorimetric measurements were carried out on the 
nanoparticles and on the pure polymers Eudragit® and PLGA. Drug loading and 
release properties of the nanoparticles were examined. The antimicrobial activity 
against Pseudomonas aeruginosa and Staphylococcus aureus was determined. During 
solvent evaporation, the size and zeta potential of the nanoparticles did not change 
significantly. The mean diameter was dependent on the presence of Eudragit® and on 
the viscosity of the organic phase. The zeta potential of all Eudragit® containing 
nanoparticles was positive in ultra pure water (around +21/+25 mV). No burst effect 
but a prolonged drug release was observed from all formulations. The particles’ 
activity against P. aeruginosa and S. aureus was comparable with an equally 
concentrated ciprofloxacin solution. 19 
 
 Different types of in situ gelling systems of indomethacin, in sodium alginate 
vehicle, were prepared and evaluated for their pharmaceutical properties including 
viscosity, sterility and drug content uniformity. The gelling efficacy of the prepared 
systems was evaluated by using an in house fabricated gelation cell. The in vitro 
release kinetics of the prepared systems was determined in simulated tear. The gelling 
time and the nature of the gel formed were dependent on the concentration of sodium 
alginate present in the systems. The drug release from these systems was extended up 
to 8 h and predominately followed zero-order kinetics. 20 
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The poor bioavailability and therapeutic response exhibited by conventional 
ophthalmic solutions due to rapid precorneal elimination of drug may be overcome by 
the use of in situ gel-forming systems that are instilled as drops into the eye and 
undergo a sol-gel transition in the cul-de-sac. The present work describes the 
formulation and evaluation of an ophthalmic delivery system of an antibacterial agent, 
gatifloxacin, based on the concept of ion-activated systems. Sodium alginate was used 
as the gelling agent in combination with hydroxy propyl methyl cellulose (Methocel 
E50LV), which acted as a viscosity enhancing agent. The developed formulations 
were therapeutically efficacious, stable, and non-irritant and provided sustained 
release of the drug over an eight hour period. The developed system is thus a viable 
alternative to conventional eye drops. 21 
 
Intra ocular implants of sodium alginate alone and in combination with 
hydroxy propyl methyl cellulose with or without calcium chloride were formulated 
with indomethacin as a model drug. The drug release from the implants was evaluated 
using static method, continuous flow through apparatus (developed in house), and 
USP dissolution and agar diffusion. Except in the static method, indomethacin particle 
size did not impart any effect on the drug release. In agar diffusion method, an 
increase in agar concentration from 1 to 2% resulted in a significant decrease 
(P<0.005) in the amount of drug released. Inclusion of hydroxypropylmethylcellulose 
(33.3, 41.6 and 50% w/w), resulted in decrease of indomethacin release irrespective of 
the method of dissolution study. The agar diffusion method and the continuous flow 
through methods seem to simulate to a certain extent the in vivo conditions as far as 
the placement of the device and the hydrodynamic diffusion layer around the intra 
ocular implant is concerned. The static method and USP method affected the 
hydrodynamic diffusion layer either too slowly or too fast. 22 
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Hypertonic ophthalmic solutions are used to treat ocular diseases associated 
with edema. In this study, we developed a chloramphenicol hypertonic ophthalmic 
solution. These drops were developed based on the co solvency and additional 
dielectric constant concepts. Two different solvents: PEG 300 and glycerol were used 
as co solvents. Solubility curves were plotted. Based on the solubility curves, two 
different solutions were selected. These solutions were evaluated for physical 
parameters and accelerated stability. The results indicated that chloramphenicol was 
stable in these formulations. The selected blend of solutions was hypertonic. Thus, the 
solubility and stability of chloramphenicol was enhanced using a co solvency 
technique so as to develop a chloramphenicol hypertonic ophthalmic solution. 23 
 
An ophthalmic gel of Diclofenac sodium, a potent non steroidal anti 
inflammatory drug was formulated using polymers of hydroxyl propyl 
methylcellulose. The gels were sterilized and assessed for various parameters like 
clarity, pH, physical appearance, physical stability, viscosity and uniformity of drug 
content. Almost 96% of drug was released from  the hydroxyl propyl methyl cellulose 
formulation within a period of 9 h is expressed in the decreasing order as follows 
hydroxyl propyl      methyl cellulose gel > methyl cellulose gel  > sodium Carboxy 
methyl cellulose gel. Ocular irritation on score basis study in rabbits reveals that none 
of the gel formulation showed any redness, inflammation or increased tear production 
when compared to placebo. Diclofenac formulation was found to be more stable in 
hydroxyl propyl methyl cellulose gel compared to methyl cellulose gel & sodium 
Carboxy methyl cellulose gel at ambient, refrigerator and incubator temperature. The 
stability of the gel was evidenced by the degradation rate constant.  Formulated 
ophthalmic gel with hydroxyl propyl methyl cellulose proves to be a viable alternative 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
37
to conventional eye drops as it offers longer pre corneal residence time and excellent 
ocular tolerance. 24 
 
Polymeric micelles made of copolymer of N-isopropylacrylamide (NIPAAM), 
vinyl pyrrolidone (VP) and acrylic acid (AA) having cross-linkage with N,N%-
Methylene bis-acrylamide (MBA) were used as host carrier in which up to 30%w:w 
ketorolac (free acid) was entrapped to make the formulation. The lyophilized powder 
was used for physical characterization. The drug entrapment was found to be about 
80% and the formulation was stable for 8–10 days at room temperature. The smaller 
the amount of ketorolac dissolved into the micelles, the longer was the formulation 
shelf life. The size of the particles as measured by dynamic light scattering was found 
to be around 35 nm diameter at 25°C. TEM picture showed spherical particles. The 
structure of the polymer and its morphology were characterized by FTIR, NMR and 
XRD measurements. IR data indicated weak interaction between polymer and 
ketorolac in the encapsulated system. NMR spectra indicated rigid polymer backbone 
with intermittent iso-propyl group in the chain. XRD spectra showed significant loss 
of crystallinity of the drug while being entrapped in the polymeric micelles. The 
releases of drug in aqueous buffer (pH 7.2) from the polymeric micelles at 25°C were 
20 and 60% after 2 and 8 h respectively and are temperature and pH dependent. In 
vitro corneal permeation studies through excised rabbit cornea indicated two fold 
increases in ocular availability with no corneal damage compared to an aqueous 
suspension containing same amount of drug as in nanoparticles. The formulation 
showed significant inhibition of lid closure up to 3 h and PMN migration up to 5 h 
compared to the suspension containing non-entrapped drug, which did not show any 
significant effect. 25 
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Diclofenac sodium ophthalmic inserts were prepared by using methyl cellulose 
(MC), sodium carboxy methyl cellulose (SCMC) alone and in combination. Weight 
variation, thickness, drug content, ocular irritation and stability of medicated inserts 
were evaluated. In vitro study was carried out by using a semi permeable dialysis 
membrane. According to the results, 97% of drug was released  from the formulation 
containing 4% SCMC and 1% MC in combination over a period of 12 h. release 
followed zero order kinetics. Medicated inserts were subjected to UV radiation and in 
vivo drug release studies. No significant change was observed in the drug content and 
physical features during storage at 30oC and 40oC for 2 months. From this study it 
was concluded that ophthalmic inserts prepared with 4% SCMC and 1% MC in 
combination showed sustained release and were found to be stable. 26 
 
The main objective of this study is to examine the therapeutic activity of 
hydrophilic glucocorticoid encapsulated in PLGA nanoparticles, which have shown 
slow release and are targeted to inflamed joints after intravenous administration, in 
experimental arthritis models. Methods: Betamethasone sodium phosphate (BSP) 
encapsulated in PLGA nanoparticles with a size of 100–200 nm (PLGA-nanosteroid) 
was prepared using modified oil in water emulsion solvent diffusion method with Zn 
ions and coated with lecithin. Rats with adjuvant arthritis (AA rats) and mice with 
anti-type II collagen antibody induced arthritis (AbIA mice) were treated 
intravenously with PLGA-nanosteroid after the initial sign of arthritis. Results: In AA 
rats, a 30% decrease in paw inflammation was obtained in 1 day and maintained for 1 
week with a single injection of 100 mg of PLGA-nanosteroid. Soft X ray examination 
7 days after this treatment showed decreased soft tissue swelling. Moreover, the 
PLGA-nanosteroid was also highly effective in AbIA mice. A single injection of 30 
mg of the PLGA-nanosteroid resulted in almost complete remission of the 
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inflammatory response after 1 week. In contrast, the same dose of free BSP after three 
administrations only moderately reduced the severity of inflammation. In addition, a 
histological examination 7 days after the treatment showed a significant decrease of 
the inflammatory cells in the joints. Conclusion: The observed strong therapeutic 
benefit obtained with PLGA-nanosteroid may be due to the targeting of the inflamed 
joint and its prolonged release in situ. Targeted drug delivery using a sustained release 
PLGA-nanosteroid is a successful intervention in experimental arthritis. 27 
 
Nanoparticles have found wide spread application in varied fields of 
engineering. Recently, core/shell nanostructures have been found to have improved 
properties when compared to their other alternatives are patented. These core/shell 
structures also interest researchers in the field of biomedical engineering and some 
potential applications have been identified. The classification of core/shell 
nanoparticles, the synthesis of these structures and their applications in the field of 
biomedical engineering are discussed in this article. The future work points at the 
possibilities of improvement and the material that might be preferred for specific 
applications. 28 
 
The purpose of this study is to test an aqueous eye drop solution containing a 
high concentration of Dexamethasone in a cyclodextrin-based drug delivery system. 
This system increases both drug solubility in aqueous eye drops and drug permeability 
into the eye, through drug-cyclodextrin- polymer co-complexes. 2-hydroxypropyl-/?-
cyclodextrin is a water-soluble oligosaccharide that can be used to dissolve lipophilic 
drugs, such as Dexamethasone, in aqueous solutions. Co-complexation with a 
polymer further increases the solubility and increases drug permeability through 
biologic membranes. Eye drops containing Dexamethasone (0.32% and 0.67%), 2-
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hydroxypropyl- /3-cyclodextrin, and polymer were given to patients before cataract 
surgery, and the resultant Dexamethasone concentration was measured from aqueous 
humor samples. The Dexamethasone -cyclodextrin drops give a significantly higher 
concentration of Dexamethasone in aqueous humor than Dexamethasone alcohol 
0.1% (Maxidex). Heating of the Dexamethasone-cyclodextrin- polymer co-complexes 
appears to enhance the permeability of the drug into the eye. The cyclodextrin-based 
drug delivery system enhances both the solubility of Dexamethasone in aqueous eye 
drops and the permeability of the drug into the human eye. Dexamethasone 
concentration levels in the human aqueous humor exceed those reported with 
currently available steroid eye drops. 29 
 
Patients with glaucoma and/or dry eye disease often require frequent dosing of 
topical medications to control their ocular disease. Detergents (such as Benzalkonium 
chloride) and oxidants (such as stabilized oxychloro complex) are commonly used as 
preservatives in multidose ophthalmic medications. A literature review was performed 
to investigate the clinical implications of preservatives in ophthalmic medications that 
are used for chronic diseases such as glaucoma and/or dry eye disease. Animal 
histopathology studies and a recent patient study found that ophthalmic medications 
with Benzalkonium chloride, unlike medications without this agent, were associated 
with lymphocyte infiltration of the conjunctiva. Ocular damage seemed to be 
correlated with the level of preservative. A recent rabbit study comparing 
Benzalkonium chloride preserved medication with stabilized oxychloro preserved 
medication, found significantly less corneal damage in the group treated with the 
latter agent. The type and amount of ophthalmic preservative that patients’ eyes are 
exposed to should be taken into account when treating patients with chronic ocular 
conditions such as glaucoma and/or dry eye disease. 30 
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The purpose of the study is to assess the potential of Chitosan (CS) 
nanoparticles for ocular drug delivery by investigating their interaction with the ocular 
mucosa in vivo and also their toxicity in conjunctival cell cultures. Fluorescent (CS-fl) 
nanoparticles were prepared by ionotropic gelation. The stability of the particles in the 
presence of lysozyme was investigated by determining the size and their interaction 
with mucin, by measuring the viscosity of the mucin dispersion. The in vivo 
interaction of CS-fl nanoparticles with the rabbit cornea and conjunctiva was analyzed 
by spectrofluorimetry and confocal microscopy. Their potential toxicity was assessed 
in a human conjunctival cell line by determining cell survival and viability. CS-fl 
nanoparticles were stable upon incubation with lysozyme and did not affect the 
viscosity of mucin dispersion. In vivo studies showed that the amounts of CS-fl in 
cornea and conjunctiva were significantly higher for CS-fl nanoparticles than for a 
control CS-fl solution, these amounts being fairly constant for up to 24 h. confocal 
studies suggest that nanoparticles penetrate into the corneal and conjunctival epithelia. 
Cell survival at 24 h after incubation with CS nanoparticles was high and the viability 
of the recovered cells was near 100%. 31 
 
Dexamethasone sodium phosphate (DSP) is the most common corticosteroid 
used in the treatment of edema paired with brain tumors (1, 2). As with other 
corticosteroids, DSP has some adverse effects on the cardiovascular, immune and 
nervous systems. The objective of this study was to minimize the adverse effects of 
DSP and to extend the release time of the drug from Microspheres by encapsulating 
with Bovine Serum Albumin (BSA). The Microspheres were prepared by emulsion 
polymerization. An aqueous solution of glutaraldehyde (25% w/v) was used as the 
cross linking agent in two different amounts. The release time DSP was found to be 
extended in the series containing 15% DSP with the increase in the amount of 
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glutaraldehyde used. Also it was observed that the release time is extended in series 
prepared using 0.5 mL glutaraldehyde with the amount of DSP. 32 
 
The development of zero-order release systems capable of delivering drug(s) 
over extended periods of time is deemed necessary for a variety of biomedical 
applications. We hereby describe a simple, yet versatile, delivery platform based on 
physically cross-linked poly (vinyl alcohol) (PVA) micro gels (cross-linked via 
repetitive freeze/thaw cycling) containing entrapped Dexamethasone-loaded poly 
(lactic co-Glycolic acid) (PLGA) Microspheres for controlled delivery over a 1-month 
period. The incorporation of polyacids, such as humic acids, Nafion, and poly (acrylic 
acid), Was found to be crucial for attaining approximately zero order release kinetics, 
releasing 60% to 75% of Dexamethasone within 1 month. Microspheres alone 
entrapped in the PVA hydro gel resulted in negligible drug release during the 1-month 
period of investigation. On the basis of a comprehensive evaluation of the structure-
property relationships of these hydrogel/microsphere composites, in conjunction with 
their in vitro release performance, it was concluded that these polyacids segregate on 
the PLGA microsphere surfaces and thereby result in localized acidity. These surface-
associated polyacids appear to cause acid-assisted hydrolysis to occur from the 
surface inwards. Such systems show potential for a variety of localized controlled 
drug delivery applications such as coatings for implantable devices. 33 
 
The pre-administration of Dexamethasone (DEX) has previously been shown 
to enhance the antitumor efficacy of chemotherapeutic agents. The delivery of anti-
inflammatory agents specifically to tumors via nanoparticle carriers is expected to 
promote the effectiveness of chemotherapeutic agents while avoiding systemic 
toxicities. The process for preparing solid lipid nanoparticles containing anti- 
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inflammatory agents using the nanotemplate engineering method was optimized. Due 
to the solubilization of DEX in the bulk aqueous phase, its more lipophilic palmitate 
ester was synthesized and incorporated in nanoparticles that included a pegylating 
agent, PEG6000 mono-stearate, as part of the formulation. The stealth properties of 
these nanoparticles were demonstrated to be enhanced compared to latex particles by 
measuring the adsorption of radio iodinated IgG (185 µg vs. 6.7 µg IgG/mg NP). In 
addition, the uptake of 14C-labeled nanoparticles by murine macrophages was shown 
to decrease from 36.6% to 14.7% of the nanoparticles/mg cell protein as the amount 
of pegylating agent in the formulation increased from 0 to 4 mg/mL. The high loading 
values and low burst effect observed for this DEX palmitate-containing nanoparticles 
in addition to their stealth properties are expected to allow for the delivery of 
sufficient amounts of DEX to tumors to enhance the uptake of chemotherapeutic 
agents. 34 
 
The objective of the present study was to develop a novel solid lipid 
nanoparticle (SLN) for the lung-targeting delivery of Dexamethasone acetate (DXM) 
by intravenous administration. DXM loaded SLN colloidal suspensions were prepared 
by the high pressure homogenization method. The mean particle size, drug loading 
capacity and drug entrapment efficiency (EE %) of SLNs were investigated. In vitro 
drug release was also determined. The biodistribution and lung-targeting efficiency of 
DXM-SLNs and DXM-solutions (DXM-sol) in mice after intravenous administration 
were studied using reversed-phase high-performance liquid chromatography (HPLC). 
The results (expressed as mean ± SD) showed that the DXM-SLNs had an average 
diameter of 552 ± 6.5 nm with a drug loading capacity of 8.79 ± 0.04% and an 
entrapment efficiency of 92.1 ± 0.41%. The in vitro drug release profile showed that 
the initial burst release of DXM from DXM-SLNs was about 68% during the first 2 h, 
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and then the remaining drug was released gradually over the following 48 hours. The 
biodistribution of DXM-SLNs in mice was significantly different from that of DXM-
sol. The concentration of DXM in the lung reached a maximum level at 0.5 h post 
DXM-SLNs injection. A 17.8-fold larger area under the curve of DXM-SLNs was 
achieved compared to that of DXM-sol. These results indicate that SLN may be 
promising lung-targeting drug carrier for lipophilic drugs such as DXM. 35 
 
Vascular endothelial growth factor (VEGF) and Dexamethasone (DX) release 
from hydrogel coatings were examined as a means to modify tissue inflammation and 
induce angiogenesis. Antibiofouling hydrogels for implantable glucose sensor 
coatings were prepared from 2-hydroxyethyl methacrylate, N-vinyl pyrrolidinone, and 
polyethylene glycol. Micro dialysis sampling was used to test the effect of the 
hydrogel coating on glucose recovery. VEGFreleasing hydrogel-coated fibers 
increased vascularity and inflammation in the surrounding tissue after 2 weeks of 
implantation compared to hydrogel-coated fibers. DXreleasing hydrogel-coated fibers 
reduced inflammation compared to hydrogel-coated fibers and had reduced capsule 
vascularity compared to VEGF-releasing hydrogelcoated fibers. Hydrogels that 
released both VEGF and DX simultaneously also showed reduced inflammation at 2 
weeks implantation; however, no enhanced vessel formation was observed indicating 
that the DX diminished the VEGF effect. At 6 weeks, there were no detectable 
differences between drug-releasing hydrogel-coated fibers and control fibers. From 
this study, hydrogel drug release affected initial events of the foreign body response 
with  DX inhibiting VEGF, but once the drug depot was exhausted these effects 
disappeared. 36 
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The ocular bioavailability of timolol increased in sorbic acid solution due to 
ion pair formation. Its octanol/water partition coefficient also increased, suggesting 
the formation of a more lipophilic complex. The concentration of timolol in rabbit 
aqueous humor was determined after instillation of timolol ophthalmic solution 
containing sorbic acid. When the molar ratio of sorbic acid to timolol was two or 
higher, the concentration of timolol in the aqueous humor was higher than with 
timolol alone. In the presence of sorbic acid the maximal aqueous humor 
concentration and the area under the curve were more than two-fold higher than those 
of Timoptol®, a timolol maleate ophthalmic solution, and similar in value to 
TIMOPTIC-XE®, a gel-forming ophthalmic solution. To investigate the transcorneal 
absorption mechanism, in vitro permeation profiles across the intact and de-
epithelialyzed cornea were analyzed on the basis of the bilayer diffusion model. The 
partition coefficient in the epithelium was about twice as high in the presence of 
sorbic acid than with timolol alone, although the diffusion coefficient in the 
epithelium did not change. We conclude that the improved ocular bioavailability in 
the presence of sorbic acid is due to increased partitioning of timolol in the corneal 
epithelium. 37 
 
Topical drug delivery systems of Fluconazole, antifungal drug in the form of 
gels were formulated using polymers like HPMC, Carbopol 934, Methylcellulose and 
Sodium alginate. The gels were evaluated for various physicochemical parameters 
like pH, viscosity, rheology, drug content, spreadibility and skin irritation test. In 
addition, in vitro drug release by diffusion using cellophane membrane and 
permeation through hairless rat skin using modified Kiesery Chien Diffusion cell was 
performed. The rheological behavior and apparent viscosity values for different gel 
bases were measured before and after storage under freezing condition at 2-8 0C and 
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were taken as measure for stability of gel network structure. Also accelerated stability 
testing at 45±2 0C and 75%±5% R.H for 3 months were performed. Among the four 
formulations, gel prepared using HPMC shows desired properties and exhibit better 
release pattern when compared with other formulations prepared with Carbopol, 
Sodium alginate and Methylcellulose. 38 
 
The poor bioavailability and therapeutic response exhibited by the 
conventional ophthalmic solutions due to pre-corneal elimination of the drug may be 
overcome by the use of in situ gel forming systems, which upon instillation as drops 
into the eye undergo a sol-gel transition in the cul-de-sac. This may result in better 
ocular availability of the drug. The purpose of this work was to develop an ophthalmic 
delivery system of the NSAID indomethacin, based on the concept of ion activated in 
situ gelation. Gelrite_ gellan gum, a novel ophthalmic vehicle, which gels in the 
presence of mono or divalent cations present in the lacrimal fluid, was used as the 
gelling agent. The developed formulations were therapeutically efficacious (in a 
uveitis induced rabbit eye model) and provided sustained release of the drug over an 
8-hour period in vitro. 39 
 
Present limitations in the management of extra ocular diseases include the 
inability to provide long-term extra ocular drug delivery without compromising 
intraocular structures and/or systemic drug exposure. In the present study, the 
potential of Chitosan (CS) nanoparticles as a new vehicle for the improvement of the 
delivery of drugs to the ocular mucosa was investigated. Cyclosporine a (CyA) was 
chosen as a model compound because of its potential usefulness for the treatment of 
these local diseases. An ionic gelation technique was conveniently modified in order 
to produce CyA-loaded CS nanoparticles. These nanoparticles had a mean size of 293 
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nm, a zeta potential of +37 mV and high CyA association efficiency and loading (73 
and 9%, respectively). In vitro release studies, performed under sink conditions, 
revealed a fast release during the first hour followed by a more gradual drug release 
during a 24-h period. In vivo experiments showed that, following topical instillation 
of CyA-loaded CS nanoparticles to rabbits, it was possible to achieve therapeutic 
concentrations in external ocular tissues (i.e., cornea and conjunctiva) during at least 
48 h while maintaining negligible or undetectable CyA levels in inner ocular 
structures (i.e., iris/ciliary body and aqueous humour), blood and plasma. These levels 
were significantly higher than those obtained following instillation of a CS solution 
containing CyA and an aqueous CyA suspension. From these results, we can conclude 
that CS nanoparticles may represent an interesting vehicle in order to enhance the 
therapeutic index of clinically challenging drugs with potential application at extra 
ocular level. 40 
 
Although eye drops are the most common form of ocular drugs, they have 
several limitations. Drug absorption into the eye is, in general, less than 5%, addition 
of preservatives is often necessary, and many drugs cannot be formulated as eye 
drops. Formulating ocular drugs as powder may solve these problems. The aim of this 
study was to investigate ocular irritation in rabbits following powder administration.  
Timolol maleate (TM) powder was administered to pigmented lop rabbits. Both pure 
TM powder and freeze-dried with PVP-polymer (2.4% of mass) were tested in 1.0- 
and 0.1-mg doses. Additionally, 4 rabbits received 0.1 mg of the pure powder 3 times 
a day for 8 d. Redness of the bulbar conjunctiva and the amount of discharge was 
rated from photographs (0–3 points, randomized and masked evaluation). The 8-d 
experiment additionally included examination with a slit lamp and examination of 
heamatoxylin-eosin stained sections of eyes with light microscopy. No serious or 
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irreversible signs of irritation were noted. Doses of 1.0 mg were more irritating than 
0.1-mg doses. There was no detectable difference in irritation between pure or freeze-
dried powder. Slit-lamp examination, surface photographs and histology showed a 
negligible difference between drug and control eyes following the 8-d experiment. 
The results suggest that 0.1 mg of timolol powder does not irritate the eye and that 
testing topical timolol powder in humans is feasible. 41 
 
Eye-drops are the conventional dosage forms that account for 90% of currently 
accessible ophthalmic formulations. Despite the excellent acceptance by patients, one 
of the major problems encountered is rapid precorneal drug loss. To improve ocular 
drug bioavailability, there is a significant effort directed towards new drug delivery 
systems for ophthalmic administration. This chapter will focus on three representative 
areas of ophthalmic drug delivery systems: polymeric gels, colloidal systems, and 
cyclodextrin and collagen shields. Hydrogels generally offer a moderate improvement 
of ocular drug bioavailability with the disadvantage of blurring of vision. In situ 
activated gel-forming systems are preferred as they can be delivered in drop form with 
sustained release properties. Colloidal systems including liposomes and nanoparticles 
have the convenience of a drop, which is able to maintain drug activity at its site of 
action and is suitable for poorly water-soluble drugs. Among the new therapeutic 
approaches in ophthalmology, cyclodextrin represent an alternative approach to 
increase the solubility of the drug in solution and to increase corneal permeability. 
Finally, collagen shields have been developed as a new continuous-delivery system 
for drugs that provide high and sustained levels of drugs to the cornea, despite a 
problem of tolerance. It seems that new tendency of research in ophthalmic drug 
delivery systems is directed towards a combination of several drug delivery 
technologies. There is a tendency to develop systems which not only prolong the 
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contact time of the vehicle at the ocular surface, but which at the same time slow 
down the elimination of the drug. Combination of drug delivery systems could open a 
new directive for improving results and the therapeutic response of non-efficacious 
systems. 42 
 
In the present update on mucoadhesive ocular dosage forms, the tremendous 
advances in the biochemistry of mucin, the development of new polymers, the use of 
drug complexes and other technological advances are discussed. This review focuses 
on recent literature regarding mucoadhesive liquid (viscous solutions, particulate 
systems), semi-solid (hydrogel, in situ gelling system) and solid dosage forms, with 
special attention to in vivo studies. Gel-forming minitablets and inserts made of 
thiomers show an interesting potential for future applications in the treatment of 
ocular diseases. 43 
 
Ocular bioavailability after instillation of carteolol was investigated by ion 
pair formation, taking into consideration a balance between lipophilicity and water 
solubility. The octanol/ water partition coefficient (PCO/W) and the aqueous humor 
concentration in rabbits after instillation of carteolol containing fatty acids having not 
more than 6 carbons were measured. The longer carbon chain fatty acid showed the 
higher PCO/W of carteolol. The aqueous humor concentration of carteolol increased 
with carbon chain length of fatty acid and was clearly correlated with logPCO/W. The 
increment of counter ion also increased both the log- PCO/W and aqueous humor 
concentration of carteolol. The findings suggested that the transcorneal absorption of 
carteolol would be designed by coordinating with quality and quantity of counter ions. 
The area under concentration (AUC) in aqueous humor applied by ion pair 
formulation containing 2% carteolol with sorbate was 2.6 times higher than that by 
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2% carteolol ophthalmic solution (control), whereas the AUC applied by 4% carteolol 
ophthalmic solution was 1.4 times higher. The plasma level after instillation of ion 
pair formulation was almost the same as that of 2% ophthalmic solution. The ratio of 
AUC (aqueous humor/ plasma) of ion pair formulation was markedly higher, as 
compared with those of 2% and 4% ophthalmic solution. These results showed that 
the ion pair formation with sorbate improved the ocular bioavailability of carteolol 
without enhancing systemic absorption. 44 
 
The aim of this study was to evaluate the effect of BAY 57-1293, a helicase-
primase inhibitor, on herpes simplex virus type 1 (HSV-1) reactivation in mice and its 
efficacy on established disease in rabbits. BALB/c mice latent for McKrae-strain 
HSV-1 were reactivated via heat stress, treated with BAY 57-1293, and their corneas 
were swabbed for virus or the trigeminal ganglia (TG) obtained for quantification of 
viral DNA. New Zealand white rabbits were infected and treated topically or orally in 
comparison with trifluridine or valacyclovir. Oral BAY 57-1293 suppressed 
reactivation in HSV-1-infected mice and reduced the viral load in TG up to            
four orders of magnitude. In the rabbits, the therapeutic efficacies of topical BAY 57-
1293 and trifluridine were similar. Once-daily oral BAY 57-1293 was significantly 
more effective than valacyclovir and as effective as twice a day topical trifluridine. 
BAY 57-1293 may be more effective than valacyclovir, without the cytotoxicity or 
potential healing retardation seen with trifluridine. Oral BAY 57-1293 may be a 
substitute for eye drops as an effective treatment for herpetic keratitis and might be 
useful in treating stromal keratitis and iritis, as well as preventing recurrences of 
ocular herpes. 45 
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Dexamethasone is a corticosteroid with proven efficacy for treating both 
anterior- and posterior-segment ocular diseases. Delivery of drugs to the back of the 
eye has always been a challenge, with Dexamethasone being no exception. There are 
multiple delivery routes to the retina, with each exhibiting different pharmacokinetics, 
depending on the drug molecule and specific route of administration. In this study, we 
used intravenous (IV), subconjunctival (SC), and intravitreal (IVT) injections in 
rabbits to determine the pharmacokinetics of Dexamethasone phosphate and its 
metabolic product, Dexamethasone, at low (25 µg/kg) and high (250 µg/kg) doses. 
Plasma samples were collected from each group of animals at different time points up 
to 24 h after the injection. Using a liquid chromatographic mass spectrometric method 
with a limit of detection of 0.5 ng/ml, the plasma concentration for Dexamethasone 
and its prodrug compound were quantified. IV delivery showed the fastest plasma 
elimination, followed by SC delivery. IVT delivery exhibited a depot effect, with very 
low plasma levels throughout the 24-h time course. At 24 h post injection, only the 
high-dose IVT and low- and high-dose SC Dexamethasone injections were still 
detectable in the plasma. 46 
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1.7.1. Summary 
Nanoparticles act as a controlled release formulation, which establishes and 
sustains the drug release at target site. The size ranges between 1 to 100 nanometers. 
The rationale behind the development and use of Nanoparticles are, 
 
 Decrease the toxicity 
 Controlling the rate and site of drug release 
 Provides a more predictable drug delivery system 
 It gives greater convenience and better patient compliance 
 They are reproducible 
 They can be freeze dried so obtained in dry powder form 
 Non- toxic and biodegradable 
 
Our aim is to sustain the action of medicament for more hours using nano 
sized formulation, for the post operative cases of cataract surgery. There by increasing 
the intact time of drug in eye which in turn helps to heal the wound faster and 
increases the patient compliance. 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
53
DRUG PROFILE 
 
DEXAMETHASONE SODIUM PHOSPHATE 
            Synonym: Dexamethasone Phosphate Sodium, Dexamethasone 21-(Disodium 
Phosphate)  
 
            Chemical Name: 9-fluoro-11β, 17-dihydroxy-16α-methyl-21-(phosphonooxy) 
pregna-1, 4-diene-3, 20-dione Disodium salt  
 
Chemical family: Corticosteroid 
Structure:  
 
 
 
 
 
Dexamethasone sodium phosphate 
 
Molecular Formula:  C
22
H
28
F Na
2
O
8
P  
Molecular Weight:                  516.41  
Physical properties:   White to almost white powder, very hygroscopic. 
Solubility: Freely soluble in water, slightly soluble in alcohol, practically 
insoluble in ether and Methylene chloride. 
Melting Point:   255°C with decomposition 
268-271°C 
262-264°C 
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Biological half-life in plasma: 2-5 hours 
Use 
Systemically and locally for chronic swelling; allergic, hematological, 
neoplastic, and autoimmune diseases; may be used in management of cerebral    
edema, septic shock, as a diagnostic agent, antiemetic. 
 
Contraindications 
Hypersensitivity to Dexamethasone or any of the component of the 
formulations are active when untreated infections; ophthalmic use in viral, fungal, or 
tuberculosis diseases of the eye. 
 
Warnings/Precautions 
Use with caution in patients with hypothyroidism, cirrhosis, hypertension, 
CHF, ulcerative colitis, or thromboembolic disorders. Corticosteroids should be used 
with caution in patients with diabetes, osteoporosis, peptic ulcer, glaucoma, cataracts, 
or tuberculosis. Use caution following acute MI (corticosteroids have been associated 
with myocardial rupture). Use caution in hepatic impairment. Because of the risk of 
adverse effects, systemic corticosteroids should be used cautiously in the elderly in 
the smallest possible effective dose for the shortest duration.  
 
Adverse Reactions 
Cardiovascular: Edema, hypertension, arrhythmia, cardiomyopathy, 
myocardial rupture (post-MI), syncope, thromboembolism, thrombophlebitis, 
vasculitis   
 
Central nervous system: Insomnia, nervousness, vertigo, seizure, psychosis, 
pseudo tumor cerebra (usually following discontinuation), headache, mood swings, 
delirium, hallucinations, euphoria  
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Dermatologic: Hirsutism, acne, skin atrophy, bruising, hyper pigmentation, 
pruritus (generalized), perianal pruritus (following I.V. injection), urticaria.  
 
Gastrointestinal: Appetite increased, indigestion, peptic ulcer, nausea, 
vomiting, abdominal distention, ulcerative esophagitis, pancreatitis, intestinal 
perforation  
 
Genitourinary: Altered (increased or decreased) spermatogenesis 
Neuromuscular & skeletal: Arthralgia, muscle weakness, osteoporosis, fractures, 
myopathy (particularly in conjunction with neuromuscular disease or neuromuscular 
blocking agents), tendon rupture, vertebral compression fractures, neuropathy, 
neuritis, parasthesia.  
 
Ocular: Cataracts, glaucoma, exophthalmos, and intraocular pressure 
increased. 
 
Miscellaneous: Infections, anaphylactic reaction, anaphylaxis, angioedema, a 
vascular necrosis, secondary malignancy, Kaposi's sarcoma, intractable hiccups, 
impaired wound healing, abnormal fat deposition, moon face  
 
Mechanism of Action 
Decreases inflammation by suppression of neutrophil migration, decreased 
production of inflammatory mediators, and reversal of increased capillary 
permeability; suppresses normal immune response. Dexamethasone mechanism of 
antiemetic activity is unknown. 
 
Actions 
Important to distinguish between physiological effects (replacement therapy) 
and pharmacological effects (occur at higher doses) 
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Mineralocorticoid 
 Na retention by renal tubule  
 increased K excretion in urine  
 
Glucocorticoid 
       CHO metabolism: increased gluconeogenesis, ± peripheral glucose uptake 
may be decreased with resultant hyperglycemia ± glycosuria protein metabolism: 
anabolism is decreased but catabolism continues unabated or is increased resulting in 
negative N balance and muscle wasting. Osteoporosis occurs, growth slows in 
children, skin atrophies (together with increased capillary fragility leads to bruising 
and striae), healing and fibrosis delayed fat deposition: increased on shoulders, face 
and abdomen inflammatory response depressed allergic response depressed antibody 
production reduced by large doses lymphoid tissue reduced (including leukemia 
lymphocytes) decreased eosinophils renal urate excretion increased euphoria or 
psychotic states may occur. ? due to CNS electrolyte changes anti-vitamin D action 
reduction of hypercalcaemia (chiefly where this is due to increased absorption from 
gut: vit D intoxication, sarcoidosis) increased urinary Ca excretion. Renal stones may 
form growth reduction where new cells are being added (eg in children) but not where 
they are replacing cells as in adult tissues suppression of HPA axis. NB steroid 
suppressed adrenal continues to secrete aldosterone  
 
Pharmacodynamics/Kinetics 
Onset of action:  Prompt  
Duration of metabolic effect: 72 hours; acetate is a long-acting repository preparation  
Metabolism: Hepatic  
Half-life elimination: Normal  
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Renal function: 1.8-3.5 hours;  
Biological half-life: 36-54 hours  
Time to peak, serum: Oral: 1-2 hours;  
I.M.: ~8 hours  
Excretion: Urine and feces  
 
Dosage 
Adults:  
Anti-inflammatory:  
Oral, I.M., I.V. (injections should be given as sodium phosphate): 0.75-9 mg/day in 
divided doses every 6-12 hours  
Intra-articular, intralesional, or soft tissue (as sodium phosphate): 0.4-6 mg/day  
Ophthalmic:  
Instill 2 drops into conjunctival sac every hour during the day and every other hour 
during the night; gradually reduce dose to every 3-4 hours, then to 3-4times/day.  
Topical: Apply 1-4times/day. Therapy should be discontinued when control is 
achieved; if no improvement is seen, reassessment of diagnosis may be necessary.  
TOXICITY: LD50:  Oral (mouse) -1800 mg/kg 
Intravenous (mouse)-112mg/kg 
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POLYMER PROFILE 
 
4.1. METHYL CELLULOSE 
Structure:  
 
Other names: Cellulose, Methyl ether; Methylated cellulose; Methylcellulose 
Nature: Methyl cellulose (or methylcellulose) is a chemical compound derived 
from cellulose. Like cellulose, it is not digestible, not toxic, and not 
allergenic. 
Solubility: It is a hydrophilic white powder in pure form and dissolves in cold (but 
not in hot) water, forming a clear viscous solution or gel. 
Chemistry: Chemically, methyl cellulose is a methyl ether of cellulose, arising 
from substituting the hydrogen atoms of some of cellulose's hydroxyl 
groups -OH with methyl groups -CH3, forming -OCH3 groups. 
 
Different kinds of methyl cellulose can be prepared depending on the number 
of hydroxyl groups so substituted. Cellulose is a polymer consisting of numerous 
linked glucose molecules, each of which exposes three hydroxyl groups. The Degree 
of Substitution (DS) of a given form of methyl cellulose is defined as the average 
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number of substituted hydroxyl groups per glucose. The theoretical maximum is thus 
a DS of 3.0; however more typical values are 1.3 - 2.6. 
 
Source: Methyl cellulose does not occur naturally and is synthetically produced 
by heating cellulose with caustic solution (e.g. a solution of sodium 
hydroxide) and treating it with methyl chloride. 
 
Solubility and temperature: 
Methyl cellulose dissolves in cold water. Higher DS-values result in lower 
solubility, because the polar hydroxyl groups are masked.  
 
The chemical is not soluble in hot water, which has the paradoxical effect that 
heating a saturated solution of methyl cellulose will turn it solid, because methyl 
cellulose will precipitate out.  
 
The temperature at which this occurs depends on DS-value, with higher DS-
values giving lower precipitation temperatures. 
 
Preparing a solution of methyl cellulose with cold water is difficult however: 
as the powder comes into contact with water, a gluey layer forms around it, and the 
inside remains dry. A better way is to first mix the powder with hot water, so that the 
methyl cellulose particles are well dispersed in the water, and cool down this 
dispersion while stirring, leading to the dissolution of those particles. 
 
Uses 
Methyl cellulose has an extremely wide range of uses, of which several are 
described below. 
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1. Scientifically Advanced Cookery 
Methyl cellulose, as a gel, has the unique property of setting when hot and 
melting when cold. This technique is currently being developed at the University of 
Nottingham. 
 
2. Treatment of constipation 
When eaten, methyl cellulose is not absorbed by the intestines but passes 
through the digestive tract undisturbed. It attracts large amounts of water into the 
colon, producing a softer and bulkier stool. It is used to treat constipation, 
diverticulosis, hemorrhoids and irritable bowel syndrome. It should be taken with 
sufficient amounts of fluid to prevent dehydration. 
 
A well-known trade name of methyl cellulose when used as a drug is Citrucel 
by GlaxoSmithKline, but generic versions are also widely available. 
 
3. Lubricant 
Methyl cellulose is used as a variable viscosity personal lubricant; it is the 
main ingredient in K-Y Jelly. 
 
4. Artificial tears and saliva 
Solutions containing methyl cellulose or similar cellulose derivatives (see 
below) are used as substitute for tears or saliva if the natural production of these fluids 
is disturbed. 
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4.2. CARBOXY METHYL CELLULOSE 
Carboxy methyl cellulose (CMC) is a cellulose derivative with carboxy methyl 
groups (-CH2-COOH) bound to some of the hydroxyl groups of the glucopyranose 
monomers that make up the cellulose backbone. It is often used as its sodium salt, 
sodium carboxy methyl cellulose. 
 
Structure: 
 
Preparation: 
It is synthesized by the alkali-catalyzed reaction of cellulose with chloroacetic 
acid. The polar (organic acid) carboxyl groups render the cellulose soluble and 
chemically reactive. 
 
The functional properties of CMC depend on the degree of substitution of the 
cellulose structure (i.e., how many of the hydroxyl groups have taken part in the 
substitution reaction), as well as the chain length of the cellulose backbone structure. 
 
Uses 
CMC is used in food science as a viscosity modifier or thickener, and to 
stabilize emulsions in various products including ice cream. As a food additive, it has 
E number E466.  
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It is also a constituent of many non-food products, such as K-Y Jelly, 
toothpaste, laxatives, diet pills, water-based paints, detergents, textile sizing and 
various paper products. It is used primarily because of it has high viscosity, is non-
toxic, and is non-allergenic.  
 
CMC is used as a lubricant in non-volatile eye drops (artificial tears). 
Sometimes it is methyl cellulose (MC) which is used, but its non-polar methyl groups 
(-CH3) do not add any solubility or chemical reactivity to the base cellulose. 
 
Insoluble micro granular carboxy methyl cellulose is used as a cation-
exchange resin in ion-exchange chromatography for purification of proteins.[1] 
Presumably the level of derivatization is much lower so that the solubility properties 
of micro granular cellulose are retained while adding sufficient negative charged 
carboxylate groups to bind positively charged proteins. 
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4.3. POLY (LACTIC-CO-GLYCOLIC ACID) PLGA 
Structure: 
 
 
x= number of units of lactic acid; y= number of units of glycolic acid. 
 
PLGA or poly(lactic-co-glycolic acid) is a copolymer which is used in a host of Food 
and Drug Administration (FDA) approved therapeutic devices, owing to its 
biodegradability and biocompatibility.  
 
Synthesis: 
PLGA is synthesized by means of random ring-opening co-polymerization of 
two different monomers, the cyclic dimers (1, 4-dioxane-2, 5-diones) of glycolic acid 
and lactic acid. Common catalysts used in the preparation of this polymer include tin 
(II) 2-ethylhexanoate, tin (II) alkoxides, or aluminum isopropoxide. During 
polymerization, successive monomeric units (of glycolic or lactic acid) are linked 
together in PLGA by ester linkages, thus yielding a linear, aliphatic polyester as a 
product.  
Depending on the ratio of lactide to glycolide used for the polymerization, 
different forms of PLGA can be obtained: these are usually identified in regard to the 
monomers' ratio used (e.g. PLGA 75:25 identifies a copolymer whose composition is 
75% lactic acid and 25% glycolic acid. All PLGA are amorphous rather than 
crystalline and show a glass transition temperature in the range of 40-60 °C. Unlike 
the homopolymers of lactic acid (polylactide) and glycolic acid (polyglycolide) which 
show poor solubility, PLGA can be dissolved by a wide range of common solvents, 
including chlorinated solvents, tetrahydrofuran, acetone or ethyl acetate. 
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PLGA degrades by hydrolysis of its ester linkages in the presence of water. It 
has been shown that the time required for degradation of PLGA is related to the 
monomers' ratio used in production: the higher the content of glycolide units, the 
lower the time required for degradation. An exception to this rule is the copolymer 
with 50:50 monomers' ratio which exhibits the faster degradation (about two months). 
In addition, polymers that are end-capped with esters (as opposed to the free 
carboxylic acid) demonstrate longer degradation half-lives. 
 
 PLGA has been successful as a biodegradable polymer because it undergoes 
hydrolysis in the body to produce the original monomers, lactic acid and glycolic acid. 
These two monomers under normal physiological conditions are by-products of 
various metabolic pathways in the body. Since the body effectively deals with the two 
monomers, there is very minimal systemic toxicity associated with using PLGA for 
drug delivery or biomaterial applications. It, however, can cause trouble for lactose 
intolerant people. Also, the possibility to tailor the polymer degradation time by 
altering the ratio of the monomers used during synthesis has made PLGA a common 
choice in the production of a variety of biomedical devices such as: grafts, sutures, 
implants, prosthetic devices, micro and nanoparticles. As an example, a commercially 
available drug delivery device using PLGA is Lupron Depot for the treatment of 
advanced prostate cancer. 
Other biodegradable polymers: 
 Polycaprolactone  
 Polyglycolide  
 Polylactic Acid  
 Poly-3-Hydroxybutyrate  
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4.4. SODIUM ALGINATE 
Synonyms:  Algin, alginic acid, sodium salt, kelcosol, manugel 
 Algin is a collective term for the hydrophillic substances isolated from certain 
brown algae commonly used genera algae are macrocystis pyrifera, laminaria digitate, 
and ascophyllum. 
Empirical Chemical Formula:    NaC6H7O6.  
 
Description:  
 A white buff colored, which is odorless. Slowly soluble in water forming a 
colloidal solution, and practically insoluble in chloroform, alcohol and ether. 
 
Its form as a gum, when extracted from the cell walls of brown algae, is used 
by the foods industry to increase viscosity and as an emulsifier. It is also used in 
indigestion tablets and the preparation of dental impressions. Sodium alginate has no 
discernible flavor. 
 
Another major use of sodium alginate is reactive dye printing, where it is used 
in the textile industry. 
 
Uses: 
A major application for sodium alginate is as thickener for reactive dyestuffs 
(such as the procion cotton-reactive dyes) in textile screen-printing and carpet jet-
printing. Alginates do not react with these dyes and wash out easily, unlike starch-
based thickeners. 
 
Sodium alginate is a good chelator for pulling radioactive toxins such as 
iodine-131 and strontium-90 from the body which have taken the place of their non-
radioactive counterparts. It is also used in immobilizing enzymes by inclusion. 
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Alginates in drug delivery system: 
 As a matrix material, the function of alginate is to release an active ingredient 
in a controlled, sustained way. This is accomplished either through erosion of tablets 
in the ventricle or by dissolution of the alginate in the small intestine. 
 
Cross- linking and gelling properties of alginates: 
 The cross linking and gelling properties of alginates is a function of both the 
alginate composition and length of the molecules. The affinity of the cross-linking 
cations for the alginate is also of great importance in gel making. Calcium is the most 
widely used cross linking agent, it is believed to interact with five different oxygen 
atoms of two adjacent guluronate units in intrachem binding. In addition, it makes an 
egg box model through intrachain binding of ca 2+ or two or more alginate chains in 
gel. 
 
 The chemical reaction between water-soluble sodium alginate and calcium 
chloride gives a water insoluble calcium alginate. But its ammonium, sodium, 
magnesium salt as well as propylene glycol esters are readily soluble in cold and hot 
water to form viscous condition. Viscosities of alginates are stable at pH 4-10. 
 
Safety: 
 Sodium alginate is widely used in food products and topical or oral 
pharmaceutical formulations. It is generally regarded as a non toxic and non irritant 
having satisfactory hemocompatability. Repeated systemic administration of alginate 
solution did not cause any adverse immunoglobulin G (IgG) and IgM humotal 
response. Also, alginates were not observed to accumulate in any of the major organs. 
The WHO has set an estimated acceptable daily intake of alginic acid and alginate 
salts used as food additives upto 25mg/kg body weight. 
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4.5. CARBOPOL 
Synonym: Carbomer, Carboxypolymethylene: 
 
Physical and Chemical Properties 
Form:     fluffy powder 
Color:     white 
Odor:     slightly acidic 
Inflammability (solid):  not inflammable 
Ignition temperature (dust):  968°F / 520°C 
Explosion hazard:   Product is non-ignitable, however development of explosive 
Minimum explosive conc.:  0.13 oz/ft3 (130 g/m3) 
Minimum ignition energy:  > 1 Joule at 0.5 kg dust /m3 air 
Vapor density:   Not volatile 
Bulk density:    (20°C) 0.19 – 0.24 g/ml 
Solubility in water:   dispersible 
pH-Value:    2.5 - 3 (10 g/l H20 / 20°C) 
 
In organic chemistry, a carbomer is an expanded molecule obtained by 
insertion of a C2 unit in a given molecule [1]. Carbomers differ from their templates in 
size but not in symmetry when each C–C single bond is replaced by at least one 
alkynes bond, and when a double bond is replaced by an allene bond. The size of the 
carbomer will continue to increase when more alkyne bonds are introduced and for 
this reason carbomers are also called carbon-molecules, where "n" is the number of 
acetylene or allene groups in an n-expansion unit. This concept, devised by Remi 
Chauvin in 1995, is aimed at introducing new chemical properties for existing 
chemical motifs. 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
68
 
Two representations exist for carbo-benzene (written as an [18]annulene 
derivative: 1,2,4,5,7,8,I0,11,13,14,16,17-dodecadehydro[18]annulene), one has the 
aromatic core of benzene expanded, and one has the hydrogen substituents expanded. 
The substituted benzene derivative hexaethynylbenzene is a known compound, [2] and 
the core-expanded molecule also exists, although with the hydrogen atoms replaced 
by phenyl groups [3]. The final step in its organic synthesis is organic oxidation of the 
triol with stannous chloride and hydrochloric acid in diethyl ether. 
 
 
 
The proton NMR spectrum for this compound shows that the phenyl protons 
are shifted downfield compared to a proton position in benzene itself (chemical shift 
position for the ortho proton is 9.49 ppm), suggesting the presence of a diamagnetic 
ring current and thus aromaticity. 
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The total carbomer of benzene with core and periphery expanded (C30H6) only 
exists in silicon [4]. 
 
Calculations predict a planar D6h structure with bond lengths similar to the 
other two carbobenzenes. Its non-planar isomer is called "hexaethynyl-carbo-[6] 
trannulene" - a pun on the all-cis annulenes - and resembles a cyclohexane ring. This 
hypothetical molecule is predicted to be more energetic by 65 kcal/mol. 
 
Other carbomer meanings 
Carbomer is also a generic name for synthetic polymers of acrylic acid used as 
emulsion stabilizers or thickening agents in pharmaceuticals and cosmetic products. 
They may be homopolymers of acrylic acid, cross linked with an allyl ether 
pentaerythritol, allyl ether of sucrose, or allyl ether of propylene. CarboMer is also a 
California-based biotechnology firm. 
 
 
 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
70
OBJECTIVE OF THE WORK 
 
  Cataract is a degradation of the optical quality of the crystalline lens. The 
development of cataract is therefore a continuum, extending from minimal changes of 
original transparency in the crystalline lens to the extreme stage of total opacity.  
 
Of the total estimated 45 million blind persons in the World, 7 million are in 
India. The main objective of National Programme for Control of Blindness is to 
reduce the prevalence of blindness in the country from 14 per 1000 to 3 per 1000 
population.  In Tamilnadu, the prevalence of blindness is 4 per 1000 population. 
 
 Postoperative regimens of topically applied antibiotics, corticosteroids, and 
NSAIDs vary among practitioners. Most commonly used Corticosteroids with 
antibiotics are,  
 
 DEXASONE (Dexamethasone sodium phosphate0.1%, Neomycin Sulphate 0.5%) 
 DECADAN (Dexamethasone sodium phosphate0.1%) 
 BETNESOL (Betamethasone sodium phosphate0.1%, Neomycin Sulphate 0.5%) 
 TOBA-DM (Dexamethasone sodium phosphate0.1%, Tobramycin Sulphate 0.3%) 
 CHLOROMET-DM (Dexamethasone sodiumphosphate0.1%, chloramphenicol 
0.3%) 
 MICROFLOX-DM (Dexamethasone 0.1%, Ciprofloxacin 0.3%) 
 OFLACIN-DX (Dexamethasone sodium phosphate0.1%, Ofloxacin 0.3%) 
 SCAT-DM (Dexamethasone sodium phosphate0.1%, Sparfloxacin 0.3%) 
 
 These are some common conventional dosage forms intended for Post cataract 
surgery which has to be instilled to eye once an hour till the inflammation suppresses 
and wound heals. This causes inconvenience to the patients. 
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 There are no controlled investigations that establish optimal regimens for the 
use of topical agents; therefore, it is the decision of the operating surgeon to use any 
or all of these products singly or in combination. Complications of postoperative 
medications include elevated IOP with corticosteroids and allergic reactions to 
antibiotics, delayed corneal healing due to patient non compliance. In order to reduce 
the side effects, non compliance, dosing frequency, indirect cost rise in post operative  
therapy due to the use of higher antibiotics ophthalmic drugs can be incorporated in 
different carriers such as Microspheres , Nanoparticles , Polymeric micelles and 
vesicular like Liposomes, Niosomes, Pharmacosomes, Virosomes.   
 
 Novel drug delivery system aims to deliver the drug at a rate directed by the 
needs of the body during the period of treatment. At present no available drug 
delivery system behaves ideally achieving lofty goals, but sincere attempts have been 
made to achieve them through novel approaches in drug delivery systems.  
 
In the treatment of post operative cases of cataract, instillation of eye drops 
containing corticosteroids with antibiotics (i-e) for every hour installation of 
medicaments is one of the major draw back for getting compliance from the patient. It 
needs nursing care.  
 
To overcome the above drawbacks we wish to formulate an ophthalmic 
preparation containing Dexamethasone sodium phosphate nanoparticles for the Post 
cataract treatment with the objectives 
 
 To enhance contact time of drug in eye, 
 To enhance the bioavailability to corneal epithelium, 
 To provide a sustained action, 
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 To reduce the dosing frequency, 
 To improve the patient compliance , 
 To study the effect of bioadhesive property of Dexamethasone sodium 
phosphate nanoparticle gel in post cataract surgery. 
 
5.1. PLAN OF WORK 
1. Construction of Standard Curve. 
2. Preparation of Ophthalmic particulate solution by solvent evaporation method. 
3. Determination of Particle size by optical Microscopical method. 
4. Dispersion of particulate solution in gels. 
5. Drug content uniformity. 
6. pH of the formulated gels. 
7. Determination of Viscosity by Brookfield Viscometer. 
8. In vitro drug release using dialysis membrane. 
9. Sterilization. 
10. In vivo studies in rabbits. 
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MATERIALS AND METHODS 
 
6.1. MATERIALS  
S.NO CHEMICALS SOURCE 
1. Dexamethasone sodium phosphate Gift sample from Appasamy 
formulations. Ltd,  Puducherry 
2. Sodium alginate Loba Chemie, Mumbai 
3. Carbopol 934 Loba Chemie, Mumbai 
4. Methyl cellulose (MC) Loba Chemie, Mumbai 
5. Carboxy Methyl cellulose(CMC) Loba Chemie, Mumbai 
6. Poly( lactic- Glycolic) acid 85:15 
(PLGA) 
Sigma-Aldrich, Hyderabad  
7. Phosphotidyl Choline Sigma-Aldrich, Hyderabad 
8. Poly Vinyl alcohol (PVA) Loba Chemie, Mumbai 
9. Dichloro methane Loba Chemie, Mumbai 
10. Dialysis membrane (M.wt.14,000) Himedia, Mumbai 
11. Polysorbate 80 Loba Chemie, Mumbai 
12. Sodium hydroxide Himedia, Mumbai 
13. Sodium Edetate Loba Chemie, Mumbai 
14. Benzalkonium Chloride Loba Chemie, Mumbai 
15. Potassium dihydrogen phosphate (AR) Himedia, Mumbai 
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INSTRUMENTS 
S.NO EQUIPMENTS MODEL 
1. Magnetic stirrer 2 MLH, Remi instruments 
2. Mechanical Stirrer RQ- 122, Remi instruments 
3. Eppendroff Centrifuge 5415, Germany  
4. UV spectrophotometer UV 1650 PC Shimadzu 
5. pH meter ELCO, LI 120 
6. Optical Microscope 806253, Olympus 
7. Electronic balance Shimadzu ELB 300 
8. Sonicator 230V  AC  50 Hz 
9. Brookfield viscometer LVDV-E, Brookfield engineering  Lab 
 
6.2. EXPERIMENTAL 
6.2.1. Construction of standard curve 
a. Preparation of Standard Stock Solution 
 Accurately, about 100 mg of Dexamethasone sodium phosphate was weighed 
and transferred to a 100 ml volumetric flask. The drug was dissolved in 100 ml of 
Phosphate buffer pH 7.4 with shaking and then the volume made up to the mark with 
Phosphate buffer pH 7.4 to obtain a standard stock solution of a drug concentration, 
1000 µg/ml.  
 
b. Selection of Analytical Wavelength 
 With appropriate dilution of the standard stock solution with Phosphate buffer 
pH 7.4, the solution was scanned using the double beam UV visible 
spectrophotometer (Model: UV- 1650 PC, SHIMADZU) in the spectrum mode between 
the wavelength range of 400 nm to 200 nm. The λmax of Dexamethasone sodium 
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phosphate was found to 242 nm, which was selected as the analytical wavelength for 
further analysis. (Fig 1) 
  Fig 1. Peak Pick of Dexamethasone Sodium Phosphate 
 
 
c. Standard Plot 
Stock solution was further diluted to different concentrations to determine the 
linearity range. Linearity was obtained in the concentration between 1-10 µg/ml. The 
standard samples were analyzed at 242 nm using UV Spectrophotometer.  (Table1 & 
Fig 2) 
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Table 1: Calibration of standard Curve 
S.No Concentration (µg/ml) Absorbance at 242 nm 
1 1 0.03006 
2 2 0.05547 
3 3 0.08313 
4 4 0.11084 
5 5 0.13775 
6 6 0.16431 
7 7 0.18944 
8 8 0.21704 
9 9 0.24243 
10 10 0.26855 
   
Fig 2: Standard Curve of Dexamethasone sodium phosphate 
 
Y = 0.02602X + 0.00744, Correlation Coefficient r2 = 0.99780 
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6.2.2. Formulation of Ophthalmic Particulate Solution by solvent evaporation 
method. 47, 48 
 It was prepared by solvent evaporation method. Dexamethasone sodium 
phosphate (0.1% by weight) was added to dichloro methane and sonicated for 3 mins. 
The organic phase was added to corresponding aqueous phase like Methyl cellulose 
(0.2 or 0.4 %), or Carboxy methyl cellulose (0.2 or 0.4%), or (PLGA (85:15), / 0.25% 
PVA and 200mg of Phosphotidyl choline solution), then magnetically stirred at 1200 
rpm at room temperature to evaporate dichloro methane (about 4 h). The particulate 
solution was obtained. (Table 2, 3, 4) 
 Drug (0.1%)      Polymer  
  +           +   
 Dichloromethane     Phosphate buffer  
 
 (Sonicated for 3mins)    Aqueous phase 
 Organic phase      
      (O/W emulsion) 
     
Primary emulsion 
 
  Mechanically    (4 hours) 
  Stirred      
     
Particulate Solution 
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            Table 2: Formulation of Particulate Solution with Methyl Cellulose 
 
METHYL CELLULOSE 
S.NO INGREDIENTS 
0.1% 0.2% 0.3% 0.4% 
1.  
Dexamethasone Sodium 
Phosphate 
0.01 gm 0.01 gm 0.01 gm 0.01 gm 
2.  Sodium Edetate 0.001 gm 0.001 gm 0.001 gm 0.001 gm 
3.  Benzalkonium chloride 0.001 gm 0.001 gm 0.001 gm 0.001 gm 
4.  Polysorbate 80 0.005 gm  0.005 gm 0.005 gm  0.005 gm  
5.  Phosphate buffer (qs) 10 ml 10 ml 10 ml 10 ml 
 
 
         Table 3: Formulation of Particulate Solution with Carboxy methyl cellulose 
 
CARBOXY METHYL CELLULOSE 
S.NO INGREDIENTS 
0.1% 0.2% 0.3% 0.4% 
1.  
Dexamethasone Sodium 
Phosphate 
0.01 gm 0.01 gm 0.01 gm 0.01 gm 
2.  Sodium Edetate 0.001 gm 0.001 gm 0.001 gm 0.001 gm 
3.  Benzalkonium chloride 0.001 gm 0.001 gm 0.001 gm 0.001 gm 
4.  Polysorbate 80 0.005 gm 0.005 gm 0.005 gm 0.005 gm 
5.  Phosphate buffer (qs) 10 ml 10 ml 10 ml 10 ml 
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Table 4: Formulation of Particulate Solution with PLGA 
S.NO INGREDIENTS For 10 ml 
1.  Dexamethasone Sodium Phosphate 0.01 gm 
2.  PLGA 0.025 gm 
3.  Phosphotidyl choline 0.2 gm 
4.  Poly vinyl alcohol 0.025 gm 
5.  Sodium Edetate 0.001 gm 
6.  Benzalkonium chloride 0.001 gm 
7.  Polysorbate 80 0.005 gm 
8.  Phosphate buffer (qs) 10 ml 
 
6.2.3. Particle Size Determination. 49 
The particulate solution was taken in a glass slide and particle size was 
determined by optical microscopy using a pre calibrated eye piece. The size of 50 
particles was measured randomly using ocular and stage micrometer. Eye piece was 
calibrated using stage micrometer at 40 X magnification. Size of each division of eye 
piece micrometer was determined using the formula 
        Number of divisions of stage micrometer 
Size of each division = --------------------------------------------------------     X 10 
                 Number of divisions of eye piece micrometer 
 
 Each division of eye piece micrometer was found to be 2 µm at 40 X 
magnification.  
 
Photo Micrographs 
 A drop of ophthalmic particulate solution was placed on the microscopic glass 
slide. Photographs of formulations were taken at 40 X magnification using the digital 
camera (Olympus, 8 mega pixels) attached to the eye piece of the microscope.        
The particle and its size are showed (Fig 3-10 & Table 5). 
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Fig .3     0.1% MC     Fig .4   0.2% MC 
    
Fig .5  0.3% MC     Fig .6  0.4% MC 
       
Fig .7  0.2% CMC     Fig .8  0.3% CMC 
   
Fig 9.  0.4% CMC      Fig 10.     PLGA 
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Table 5: AVERAGE PARTICLE SIZE IN FORMULATION 
S.NO POLYMER PARTICLE SIZE ( µm ) 
1. 0.1% MC 3.88 
2. 0.2% MC 2.4 
3. 0.3% MC 3.63 
4. 0.4% MC 5.26 
5. 0.2% CMC 2.28 
6. 0.3% CMC 3.56 
7. 0.4% CMC 2.34 
8. PLGA 2.22 
 
 
6.2.4. Dispersion of particulate solution in gels. 
The ophthalmic particulate solutions were taken and mixed with the specified 
quantity of Sodium Alginate (1% or 3%) or Carbopol (0.1%) correspondingly, and 
trituration was continued for 1 hour till the particulate solution was dispersed and to 
get a gel consistency. 
 
6.2.5. Drug content uniformity. 20 
The vials containing the preparations were shaken for a few minutes and     
100 µl of the preparations were transferred to 25 ml volumetric flasks using a Micro 
Pipette. Phosphate buffer (pH 7.4) was added in small portions (5 ml), shaken to 
dissolve the contents, volume was adjusted to 25 ml, and the solutions were assayed 
for Dexamethasone sodium phosphate content at 242 nm.(Table 13.) 
Drug Content Uniformity =  Concentration x 1 x Dilution Factor 
      1000 
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6.2.6. pH. 38 
2.5 gm of gel was accurately weighed and dispersed in 25 ml of purified 
water. The pH of dispersions was measured using pH meter. (Table 6) 
 
Table 6: COMPARATIVE PROFILE OF DRUG CONTENT UNIFORMITY 
AND pH OF FORMULATED GELS 
S.NO CONTENT % UNIFORMITY pH 
1% SODIUM ALGINATE GEL 
1 0.2% MC 77.36 7.2 
2 0.2% CMC 41.8 7.34 
3 0.4% CMC 60.56 7.12 
4 PLGA 87.57 7.42 
3% SODIUM ALGINATE GEL 
5 0.2% MC 79.17 7.18 
6 0.2% CMC 64.4 7.32 
7 0.4% CMC 14.2 7.16 
8 PLGA 75.27 7.38 
0.1% CARBOPOL GEL 
9 0.2% MC 18.8 7.22 
10 0.2% CMC 13.0 7.3 
11 0.4% CMC 14.9 7.1 
12 PLGA 24.75 7.4 
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6.2.7. VISCOSITY AND RHEOLOGICAL STUDIES. 21 
Viscosity of formulated gels was determined using Brookfield Viscometer. 
Gels were tested for their rheological characteristics at 250C using Brookfield 
Viscometer (LVDV-E Brookfield engineering Lab) spindle no 62. The measurement 
was made over with the speed 30 rpm. (Table 7) 
Table 7: VISCOSITY PROFILE OF OPHTHALMIC GELS 
 
 
6.2.8. IN VITRO DRUG RELEASE.  
         In vitro release from formulation was carried out by dialysis membrane 
diffusion technique (obtained from Hi-Media) having a molecular weight cut off 
12000. The membrane used was transparent and regenerated cellulose type, which 
was permeable to low molecular weight substances. The release study of the gel was 
performed by 1ml ophthalmic gel in a dialysis bag and then immersed in phosphate 
buffer (pH 7.4).The receptor compartment was continuously stirred (50 rpm) using a 
magnetic stirrer. The temperature was maintained between 37° ± 1°C. Samples were 
withdrawn at predetermined time intervals and the same volume was replaced with 
S.NO CONTENT VISCOSITY (cps) at 30 rpm 
1% SODIUM ALGINATE GEL 
1 0.2% MC 52 
2 0.2% CMC 198 
3 0.4% CMC 493 
3% SODIUM ALGINATE GEL 
5 0.2% MC 189 
6 0.2% CMC 588 
7 0.4% CMC 994 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
84
fresh buffer medium to maintain sink condition. The absorbance of the withdrawn 
sample was measured after suitable dilution. At various time intervals, aliquot 
samples was withdrawn and assayed for drug content by UV spectrophotometer 
method. Drug release profiles were plotted by taking time on X axis and percentage 
release on Y axis. The in vitro release data and comparative invitro release profile of 
corresponding gels are showed in Table 8-15 and Fig 11-14. . 
  
Table 8: IN VITRO RELEASE DATA OF 1% SODIUM ALGINATE GEL: 
Table 8.1: 0.2% MC 
          n = 2 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative 
% Release 
30 0.01501 0.29093 0.000291 0.29093 29.0930±1.49
60 0.0199 0.478862 0.000479 0.478862 47.8862±1.38
90 0.02625 0.722905 0.000723 0.722905 72.2905±1.39
120 0.03088 0.900846 0.000901 0.900846 90.0845±1.52
 
Table 8.2: 0.2% CMC 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative 
% Release 
30 0.03503 1.060338 0.00106 0.106034 10.60338 
60 0.05383 1.782859 0.001783 0.178286 17.82859 
90 0.06445 2.191007 0.002191 0.219101 21.91007 
120 0.07532 2.608762 0.002609 0.260876 26.08762 
150 0.09375 3.317064 0.003317 0.331706 33.17064 
180 0.10364 3.697156 0.003697 0.369716 36.97156 
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Table 8.3: 0.4% CMC 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative 
% Release 
30 0.00781 0.01422 1.42E-05 0.01422 1.421983 
60 0.01704 0.368947 0.000369 0.368947 36.8947 
90 0.02551 0.694466 0.000694 0.694466 69.44658 
120 0.03308 0.985396 0.000985 0.985396 98.53958 
 
Table 8.4: PLGA 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative 
% Release 
30 0.02148 0.539585 0.00054 0.053958 5.395849 
60 0.02649 0.732129 0.000732 0.073213 7.321291 
90 0.03491 1.055726 0.001056 0.105573 10.55726 
120 0.03528 1.069946 0.00107 0.106995 10.69946 
150 0.047 1.520369 0.00152 0.152037 15.20369 
180 0.05298 1.750192 0.00175 0.175019 17.50192 
210 0.05518 1.834743 0.001835 0.183474 18.34743 
240 0.06226 2.106841 0.002107 0.210684 21.06841 
270 0.06763 2.313221 0.002313 0.231322 23.13221 
300 0.09501 3.365488 0.003365 0.336549 33.65488 
 
 
 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
86
Fig 11: COMPARATIVE RELEASE PROFILE OF  
1% SODIUM ALGINATE GELS 
 
Table 9: COMPARATIVE RELEASE PROFILE OF  
1% SODIUM ALGINATE GELS 
CUMULATIVE % DRUG RELEASE OF 1% SODIUM 
ALGINATE GEL 
TIME IN 
MINS 
0.2% MC 0.2% CMC 0.4% CMC PLGA 
0 0 0 0 0 
30 29.0930±1.49 10.60338 1.421983 5.395849 
60 47.8862±1.38 17.82859 36.8947 7.321291 
90 72.2905±1.39 21.91007 69.44658 10.55726 
120 90.0845±1.52 26.08762 98.53958 10.69946 
150 - 33.17064 - 15.20369 
180 - - - 17.50192 
210 - - - 18.34743 
240 - - - 21.06841 
270 - - - 23.13221 
300 - - - 33.65488 
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Table 10: IN VITRO RELEASE DATA OF 3% SODIUM ALGINATE GEL: 
Table 10.1: 0.2% MC 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative 
% Release 
30 0.0415 1.308993 0.001309 0.130899 13.08993 
60 0.09338 3.302844 0.003303 0.330284 33.02844 
90 0.11194 4.016141 0.004016 0.401614 40.16141 
120 0.18835 6.952729 0.006953 0.695273 69.52729 
 
Table 10.2: 0.2% CMC 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative 
% Release 
30 0.00159 -0.22483 -0.00022 -0.22483 0 
60 0.00089 -0.25173 -0.00025 -0.25173 0 
90 0.01599 0.328593 0.000329 0.328593 32.85934 
120 0.02942 0.844735 0.000845 0.844735 84.47348 
150 0.03345 0.999616 0.001 0.999616 99.96157 
 
Table 10.3: 0.4% CMC 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative 
% Release 
30 0.02283 0.591468 0.000591 0.591468 59.14681 
60 0.02734 0.764796 0.000765 0.764796 76.47963 
90 0.00281 0.00281 0.00281 0.00281 0.00281 
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Table 10.4: PLGA 
         n = 2 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative 
% Release 
30 0.01221 0.183321 0.000183 0.183321 18.3320±1.36
60 0.01965 0.469254 0.000469 0.469254 46.9254±1.89
90 0.02734 0.764796 0.000765 0.764796 76.4796±1.9 
120 0.2229 8.280553 0.008281 0.828055 82.8055±1.68
150 0.22583 8.393159 0.008393 0.839316 83.9315±1.54
180 0.24976 9.312836 0.009313 0.931284 93.1283±1.06
210 0.26624 9.946195 0.009946 0.99462 99.4619±0.38
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Fig 12: COMPARATIVE RELEASE PROFILE OF 
3% SODIUM ALGINATE GELS 
 
Table 11: COMPARATIVE RELEASE PROFILE OF 
3% SODIUM ALGINATE GELS 
 
CUMULATIVE % DRUG RELEASE OF 3% SODIUM 
ALGINATE GEL 
TIME IN 
MINS 
0.2% MC 0.2% CMC 0.4% CMC PLGA 
0 0 0 0 0 
30 13.08993 0 59.14681 18.3320±1.36 
60 33.02844 0 76.47963 46.9254±1.89 
90 40.16141 32.85934 - 76.4796±1.9 
120 69.52729 84.47348 - 82.8055±1.68 
150 - 99.96157 - 83.9315±1.54 
180 - - - 93.1283±1.06 
210 - - - 99.4619±0.38 
240 - - - - 
270 - - - - 
300 - - - - 
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Table 12: IN VITRO RELEASE DATA OF 0.1% CARBOPOL GEL: 
Table 12.1: 0.2% MC 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative 
% Release 
30 0.0365 1.116833 0.001117 0.111683 11.16833 
60 0.07373 2.547656 0.002548 0.254766 25.47656 
90 0.09534 3.378171 0.003378 0.337817 33.78171 
120 0.10889 3.898924 0.003899 0.389892 38.98924 
150 0.12231 4.414681 0.004415 0.441468 44.14681 
180 0.13501 4.902767 0.004903 0.490277 49.02767 
210 0.15625 5.719062 0.005719 0.571906 57.19062 
240 0.17749 6.535357 0.006535 0.653536 65.35357 
270 0.21167 7.848962 0.007849 0.784896 78.48962 
 
Table 12.2: 0.2% CMC 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative 
% Release 
30 0.01123 0.145657 0.000146 0.014566 1.456572 
60 0.02368 0.624135 0.000624 0.062414 6.241353 
90 0.02686 0.746349 0.000746 0.074635 7.46349 
120 0.03345 0.999616 0.001 0.099962 9.996157 
150 0.03711 1.140277 0.00114 0.114028 11.40277 
180 0.08203 2.866641 0.002867 0.286664 28.66641 
210 0.08838 3.110684 0.003111 0.311068 31.10684 
240 0.09717 3.448501 0.003449 0.34485 34.48501 
270 0.11511 4.137971 0.004138 0.413797 41.37971 
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Table 12.3: 0.4% CMC 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative 
% Release 
30 0.01184 0.169101 0.000169 0.01691 1.691007 
60 0.00708 -0.01384 -1.4E-05 -0.00138 -0.13836 
90 0.02173 0.549193 0.000549 0.054919 5.491929 
120 0.04639 1.496925 0.001497 0.149693 14.96925 
150 0.0614 2.073789 0.002074 0.207379 20.73789 
180 0.073 2.5196 0.00252 0.25196 25.196 
210 0.08704 3.059185 0.003059 0.305919 30.59185 
 
Table 12.4: PLGA 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative 
% Release 
30 0.02698 0.750961 0.000751 0.075096 7.509608 
60 0.0448 1.435819 0.001436 0.143582 14.35819 
90 0.07373 2.547656 0.002548 0.254766 25.47656 
120 0.06897 2.364719 0.002365 0.236472 23.64719 
150 0.08228 2.876249 0.002876 0.287625 28.76249 
180 0.0968 3.434281 0.003434 0.343428 34.34281 
210 0.10693 3.823597 0.003824 0.38236 38.23597 
240 0.11182 4.01153 0.004012 0.401153 40.1153 
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Fig 13: COMPARATIVE RELEASE PROFILE OF 0.1% CARBOPOL GEL 
 
Table 13: COMPARATIVE RELEASE PROFILE OF 0.1% CARBOPOL GEL 
CUMULATIVE % DRUG RELEASE OF 0.1% CARBOPOL 
GEL 
TIME IN 
MINS 
0.2% MC 0.2% CMC 0.4% CMC PLGA 
0 0 0 0 0 
30 11.16833 1.456572 1.691007 7.509608 
60 25.47656 6.241353 -0.13836 14.35819 
90 33.78171 7.46349 5.491929 25.47656 
120 38.98924 9.996157 14.96925 23.64719 
150 44.14681 11.40277 20.73789 28.76249 
180 49.02767 28.66641 25.196 34.34281 
210 57.19062 31.10684 30.59185 38.23597 
240 65.35357 34.48501 - 40.1153 
270 78.48962 41.37971 - - 
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Table 14: IN VITRO RELEASE DATA OF DRUG IN SOLUTION: 
n = 2 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative 
% Release 
15 0.0681 2.331284 0.002331 0.233128 
23.3128 ± 
0.93 
30 0.1244 4.495004 0.004495 0.4495 
44.9500 ± 
1.34 
45 0.1996 7.385088 0.007385 0.738509 
73.8508 ± 
0.52 
           
Fig 14: RELEASE PROFILE OF DRUG IN SOLUTION 
 
 
Table 15: RELEASE PROFILE OF DRUG IN SOLUTION 
TIME IN MINS CUMULATIVE % RELEASE 
0 0 
15 23.3128 ± 0.93 
30 44.9500 ± 1.34 
45 73.8508 ± 0.52 
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DRUG RELEASE KINETICS 
 
6.2.8.1. 0.2% MC IN 1% SODIUM ALGINATE GEL. 
 
Fig 15: ZERO ORDER RELEASE of 0.2% MC 
 
 
 
Fig 16: FIRST ORDER RELEASE of 0.2% MC 
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Fig 17: HIGUCHI PLOT of 0.2% MC 
 
 
Fig 18: KORSMEYER PEPPAS PLOT of 0.2% MC 
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6.2.8.2. PLGA IN 3% SODIUM ALGINATE GELS 
 
Fig 19: ZERO ORDER RELEASE of 0.2% PLGA 
 
 
Fig 20: FIRST ORDER RELEASE of 0.2% PLGA 
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Fig 21: HIGUCHI PLOT of 0.2% PLGA 
 
 
Fig 22: KORSMEYER PEPPAS PLOT of 0.2% PLGA 
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6.2.9. STERILIZATION. 
 Sterilization of the ophthalmic gels was carried by moist heat sterilization. The 
ophthalmic gels were autoclave at 121oC for 20 mins. 
 
6.2.10. IN VIVO STUDIES. 
 The animal ethical committee (PSG Institute of Medical Sciences and 
Research, Reg no:  158/ 1999/ CPCSEA, dated on 5th Jan 2009) had given permission 
for the in vivo study. The healthy albino rabbits were taken (weighing 1.5 to 2 kg). 
The animals with any ocular abnormalities were excluded after thorough examination. 
The animals were housed in individual cages. The drug content present in aqueous 
humor, of the ophthalmic gel formulation and Drug in solution was determined using 
three groups of healthy rabbits (A, B & C) four each. The rabbits were anesthetized 
with intramuscular injection of Ketamine (40 mg/kg).  
 
Fig 23: Collection of Aqueous Humor 
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Aqueous humor (50 µl) was collected (Fig 23) by using a syringe connected to 
a 30- gauge needle in the sclero-corneal limbus. The aqueous humor was collected at 
every 15 mins interval for 1 hour. The absorbance of the withdrawn sample was 
measured after suitable dilution with phosphate buffer and assayed for drug content 
by UV spectrophotometer method at 242 nm. The in vivo release data was showed in 
Table 16- 18.     The comparative in vivo release profile showed in Fig 24 & Table 19. 
 
Table 16: IN VIVO RELEASE DATA OF 0.2% MC IN  
1% SODIUM ALGINATE GEL 
n = 4 
Time 
in 
Mins 
Absorbance 
in nm 
Concentratio
n in mcg/ml 
Concentration 
in mg 
Concentratio
n in 10 ml 
Cumulative % 
Release 
15 0.21924 8.139892 0.00814 0.244197 24.41968 ± 0.48
30 0.34521 12.98117 0.012981 0.389435 38.9435 ± 1.40 
45 0.62781 23.84204 0.023842 0.715261 71.52613 ± 1.28
60 0.6626 25.17909 0.025179 0.755373 75.53728 ± 0.69
           
Table 17: IN VIVO RELEASE DATA OF PLGA IN  
3% SODIUM ALGINATE GEL 
Time 
in 
Mins 
Absorbance 
in nm 
Concentratio
n in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative % 
Release 
15 0.11865 4.27402 0.004274 0.128221 12.82206 ± 0.93 
30 0.18274 6.737125 0.006737 0.202114 20.21138 ± 0.36 
45 0.71533 27.20561 0.027206 0.816168 81.61683 ± 0.93 
60 0.72241 27.47771 0.027478 0.824331 82.43313 ± 0.56 
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Table 18: IN VIVO RELEASE DATA OF DRUG IN SOLUTION 
 
n = 4 
Time 
in 
Mins 
Absorbance 
in nm 
Concentration 
in mcg/ml 
Concentration 
in mg 
Concentration 
in 10 ml 
Cumulative % 
Release 
15 0.35571 13.3847 0.013385 0.401541 40.15411 ± 0.59
30 0.74915 28.50538 0.028505 0.855161 85.51614 ± 1.2 
           
 
Fig 24: COMPARATIVE IN VIVO RELEASE PROFILE OF  
OPHTHALMIC GELS: 
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Table 19: COMPARATIVE IN VIVO RELEASE PROFILE OF  
OPHTHALMIC GELS 
 
PERCENTAGE RELEASE TIME IN 
MINS F1 F2 F3 
30 40.15411 ± 0.59 24.41968 ± 0.48 12.82206 ± 0.93 
60 85.51614 ± 1.2 38.9435 ± 1.40 20.21138 ± 0.36 
90 - 71.52613 ± 1.28 81.61683 ± 0.93 
120 - 75.53728 ± 0.69 82.43313 ± 0.56 
 
6.2.11. STATISTICAL ANALYSIS: 
Comparison between the in vivo release in 0.2% MC in 1% sodium alginate 
gel and PLGA in 3% sodium alginate gel was performed by Analysis of Variance 
(one way ANOVA with Turkeys multiple comparison post test) with graph pad prism 
(version 3.0) software. 
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RESULTS AND DISCUSSION 
 
7.1. Construction of standard graph: 
 The pure drug Dexamethasone sodium phosphate solution was analyzed 
spectrophotometrically at 242 nm. Linearity was found to be in the concentration     
(1-10 µg/ml) and the r2 value was found to be 0.99780. (Fig-1, 2 & Table-1) 
 
7.2. Formulation of ophthalmic particulate solution: 
 The ophthalmic particulate formulation was formulated using solvent 
evaporation method. The particles in the particulate solutions were found to be good 
and visible in the formulation prepared with 0.2% MC, 0.2% CMC, 0.4% CMC and 
PLGA. Hence these formulations were selected for the further investigations. (Table 
2, 3) 
 
7.3. Particle Size 
The particle size in the prepared formulation was found to be less in PLGA 
(2.22 µm) and bigger in 0.4% MC (5.26 µm), (Table 5). Formulation with 0.2% MC 
and 0.2 CMC were also found to be smaller. Microparticles 49 (mean diameter 1-3 
µm) may be better suited for controlled release, but the presence of coarse particle 
above 25 µm makes them less tolerable and cause irritation to the eye. This confirms 
formulated particulate ophthalmic solutions are within the limit. 
 
7.4. Drug Content uniformity and pH 
The drug content uniformity in 1% & 3% sodium alginate gel with PLGA and 
0.2% MC was seemed to be high as 87.57%, 77.36% and 75.27%, 79.17%. 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
103
 Even though drug content uniformity in PLGA and 0.2% MC were seemed to 
be higher in Carbopol gel, the drug content uniformity is less when compared with 
sodium alginate formulations (1% & 3%). (Table 6) 
 
The pH of all ophthalmic formulated gels (1% & 3% Sodium alginate gel and 
0.1% Carbopol gel) was found to be in limit (pH 7-7.5). (Table 6) 
 
7.5. Viscosity of Gels. 
When the Nanoparticulate solutions dispersed in lower polymer 
concentrations, (i.e.) 1% sodium alginate gel the viscosity was found to be low. When 
the polymeric concentration (3 % sodium alginate gel) increased the viscosity seems 
to be increased.  
 
Generally viscosity values in the range of 15-50 cps significantly improve the 
contact time in the eye. The viscosity range of 3% sodium alginate gels are 3- 4 times 
higher than that of 1% sodium alginate gel. Viscosity values are promising; hence it 
may increase the contact time in conjunctival sac during application. (Table 7) 
 
7.6. IN VITRO RELEASE STUDIES. 
 The release data of ophthalmic gels are showed in Table 8-15 & Fig 11-14. 
Drug release from 1% sodium alginate gel, with the formulation Methyl cellulose 
(0.2%) shows 90.08% at 120 mins, where as Carboxy methyl cellulose (0.2%) was 
26.12% in 120 mins, the release after 150 mins from CMC was 33.17%.  
 
The higher polymeric concentration of Carboxy methyl cellulose (0.4%) 
shows 98.53% at 120 mins.  
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 The release from 0.2% MC & 0.4% CMC shows the maximum percentage 
release of about 90% at 120 mins.  
 
The release profile from PLGA formulation was found to be 33.65% at 300 
mins. (Fig 11) 
 
 Drug release from 3% sodium alginate gel shows 69.52% of release in lowest 
polymeric concentration of Methyl cellulose (0.2%) at 120 mins; where as the drug 
release was not found from the Carboxy methyl cellulose (0.2%) in the initial hours. 
 
 Formulation containing carboxy methyl cellulose (0.4%) concentration 
dispersed in 3% sodium alginate gel shows 76.47% of drug in 60 mins. 
 
 PLGA shows the release of 82.80% at 120 mins, and it extends upto 210 mins 
where release of drug was 99.46%. 
 
From the release study of 3% sodium alginate gel 0.2% MC and PLGA shows 
the maximum percentage release. (Fig 12) 
 
 Formulation was dispersed in 1% and 0.5% Carbopol gel and the drug was not 
released from this formulation even after 2 hour. 
 
From the 0.2% MC formulation dispersed in 0.1% Carbopol the release was 
found to be 78.48% in 270 mins.  
 
Formulations 0.2% CMC, 0.4% CMC and PLGA were dispersed in 0.1% 
Carbopol gel found that the release was less than 40% of drug in 270 mins. Hence 
these formulations were not taken for further studies. (Fig 13) 
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   The release data of drug in solution shows 73.85% of drug released in 
45mins (Fig 14) 
 
  The drug released from 0.2% MC in 1% sodium alginate gel & 3% sodium 
alginate was 90.08% & 69.52% at 120 mins, where as PLGA in 1% sodium alginate 
gel & 3% sodium alginate was 33.65% & 99.46% in 210 mins. The formulations, 
0.2% MC in 1% sodium alginate gel and PLGA in 3% sodium alginate gels were 
selected for further studies.  
 
 The in vitro drug release from 0.2% MC in 1% sodium alginate gel & PLGA 
in 3% sodium alginate gel was about 20% in the initial 30 mins. 
 
The difference in drug release from the formulation may be due to the  
¾ Polymeric concentration in the particulate formulation 
¾ Permeation of  gel through the dialysis membrane and  
¾ Diffusion of  drug particulates from the formulation into the gel  
 
From the kinetics data, the regression value for Higuchi plot shows the release 
from both formulations 0.2% MC in 1% sodium alginate gel and PLGA in 3% sodium 
alginate gel follow diffusion.  
 
From the slope value of korsmeyer Peppas plot 0.2% MC in 1% sodium 
alginate gel follows non fickian diffusion type of release and PLGA in 3% sodium 
alginate gel follows analomous type diffusion (diffusion and erosion).(Fig 15-22) 
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7.7. IN VIVO STUDIES. 
 Percentage of drug release in the aqueous humor from drug in solution  (F1) 
was 85.51% at 60 mins (Table 16), where as 0.2% MC in 1% sodium alginate gel (F2) 
& PLGA in 3% sodium alginate gel (F3) it was 75.53% & 82.42% at 120 mins (Table 
17, 18).  
 
Both the formulations F2 & F3 were found to be effective in extending the 
drug release. Formulation (0.2% MC in 1% sodium alginate gel) F2 seemed to be the 
best formulation than PLGA in 3% sodium alginate gel (F3). (Fig 24, Table 19).  
  
The drug concentration in aqueous humor was found to increase significantly 
(P< 0.001) in formulation F1 when compared with formulation F2 & F3. 
 
But when the formulations F2 & F3 were compared F2 was seemed to be 
significant (P<0.001) at 60 mins. 
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CONCLUSION 
 
From above results we conclude that gel formulation prepared with 0.2% MC 
in 1% sodium alginate and PLGA in 3% sodium alginate gives promising results in 
viscosity, drug content uniformity, and in vitro studies.  
  
Nanoparticulate formulation 0.2% MC dispersed in 1% sodium alginate gel 
(F2) found to have significant (P<0.001) drug concentration in the rabbit aqueous 
humour than the formulation PLGA in 3% sodium alginate gel (F3).  
 
From the in vivo drug release, the formulation F2 (0.2% MC in 1% sodium 
alginate gel) confirms that the drug release can be extended upto 2 to 2.5 hours 
through the nanoparticulate formulation for the post cataract treatment. 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
108
 
BIBLIOGRAPHY 
 
1. Vyas, S.P., Khar, R.K., Targeted & Controlled Drug Delivery, Novel Carrier 
Systems., CBS Publishers & Distributors, New Delhi. 2002, 42-85. 
2. Jain.N.K.,  Advances in controlled and novel drug delivery.,  1st edition, 2006, 
89-92 
3. Soppimath, K.S., Aminabhari, T.M., Kulkarni, A.R., Rudzinski, W.E., J. 
Contr. Rel., 2001, 70,1-20. 
4. Ogawa,Y., Okada, H., Heya, T., Shimamoto, T., J. Pharm. Pharmacol., 1989, 41, 
439-444. 
5. Astete,C.E.,Sabliov,C.M., J. Biomater. Sci. Polymer Edn, 2006, 17(3), 247-289. 
6. Avgoustakis, K., Curr Drug Deliv., 2004, 1, 321-333. 
7. Fessi, H., Devissaguet, J.P., Puisieux, F., Ammoury, N., Benita, S., Int. J. 
Pharm., 1989, 55, R1-R4. 
8. Swarbrick, J., Boylan, J.C., Encyclopedia of Phamaceutical Technology., 2nd 
edition, 2, 2002, 1865 – 1867. 
9. A.J.Domb., M.N.V.Ravi kumar., Nanoparticles for Pharmaceutical 
Applications, AS publications, 2007, 367-376 
10. Arto Urtti et al., Challenges and Obstacles of Ocular Pharmacokinetics and 
Drug Delivery.,  Advanced Drug Delivery Reviews 58 (2006) 1131–1135 
11. Basavaraj, K., Nanjawade., et al., In Situ-Forming Hydrogels For Sustained 
Ophthalmic Drug Delivery.,  Journal of Controlled Release 122 (2007) 119–134 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
109
 
12. V.M.  Loganathan.MS.DO., ATLAS OF CLINICAL., 2nd edition P.no 90-95 
13. Xiuling Lu., Melissa D., Howard, Marta Mazik., et al.,  Nanoparticles 
Containing Anti-Inflammatory Agents as Chemotherapy Adjuvants: 
Optimization and In Vitro Characterization., American Association of 
Pharmaceutical Scientists Journal, Vol. 10, No. 1, March 2008 
14. Sveinn hákon hardarson., hákon hrafn sigurdsson., et al., Ocular Powder: Dry 
Topical Formulations of Timolol are Well Tolerated in Rabbits., Journal of 
ocular pharmacology and therapeutics Volume 22, Number 5, 2006 
15. Carolina G´omez-Gaete., Nicolas Tsapis., et al., Encapsulation of 
Dexamethasone into biodegradable polymeric nanoparticles.,  International 
Journal of Pharmaceutics 331 (2007) 153–159 
16. Dong-Hwan Kima., David C. Martina., et al.,  Sustained release of 
Dexamethasone from hydrophilic matrices using PLGA nanoparticles for 
neural drug delivery., Biomaterials 27 (2006) 3031–3037 
17. Angela M. de Campos., Maria José Alonso., et al., Chitosan Nanoparticles as 
New Ocular Drug Delivery Systems: in vitro Stability, in vivo Fate, And 
Cellular Toxicity., Pharmaceutical Research, Vol. 21, No. 5, May 2004  
18. Roberta Cavalli., M. Rosa Gasco., et al., Solid Lipid Nanoparticles (SLN) as 
Ocular Delivery System for Tobramycin., International Journal of 
Pharmaceutics 238 (2002) 241–245 
19. Kathleen Dillen., Jo Vandervoort., et al., Evaluation of Ciprofloxacin-Loaded 
Eudragit® RS100 Or Rl100/PLGA Nanoparticles., International Journal of 
Pharmaceutics 314 (2006) 72–82 
 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
110
 
20. JK Pandit., D Bharathi., et al.,  Long Acting Ophthalmic Formulation of 
Indomethacin: Evaluation of Alginate Gel Systems.,  International Journal of 
Pharmaceutics Vol 69  Year : 2007 Issue  ( 1) 37-40 
21. RC Doijad., V.S.N Malleswara Rao., et al., Sustained   Ophthalmic Delivery of 
Gatifloxacin from in Situ Gelling System.,  International Journal of 
Pharmaceutics Vol 68 ; 2006 Issue ( 6 ) 814-818 
22. JBalasubramaniam., JK Pandit., et al., Studies on Indomethacin Intraocular 
Implants Using Different in Vitro Release Methods.,  International Journal of 
Pharmaceutics Vol 70 ;2008 Issue : (2)216-221 
23. AV Jithan., C Krishna Mohan., M Vimaladevi., Development and  Evaluation of 
a Chloramphenicol Hypertonic Ophthalmic Solution.,  International Journal of 
Pharmaceutics Vol 70 ; 2008 Issue  (1) 66-70 
24. V.Sankar., A.K.Chandrasekaran., S.Durga., et al., Formulation and Stability 
Evaluation Of Diclofenac Sodium Ophthalmic Gels., International Journal of 
Pharmaceutics Vol 67; 2005 issue (4) 473-476. 
25. Ajay Kumar Gupta., Sumit Madan., et al., Ketorolac Entrapped in Polymeric 
Micelles: Preparation, Characterisation and Ocular Anti-Inflammatory 
Studies.,  International Journal of Pharmaceutics 209 (2000) 1–14 
26. V.Sankar., A.K.Chandrasekharan., S.Durga., et al., Design And Evaluation Of 
Diclofenac Sodium Ophthalmic Inserts., Acta Pharmaceutica sciencia 48: 5-10 
(2006) 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
111
 
27. Higaki., Ishihara., Izumo, et al., Treatment of Experimental Arthritis with Poly 
(D,L Lactic  /Glycolic Acid) Nanoparticles Encapsulating Betamethasone 
Sodium Phosphate., Ann Rheum Dis 2005; 64 : 1132 – 1136 
www.annrheumdis.com 
28.  Nagarajan Sounderya., Yong Zhang., et al.,   Use Of Core/Shell Structured 
Nanoparticles For Biomedical Applications., Recent Patents on Biomedical 
Engineering, 2008, Vol. 1, No. 1 
29. Johannes Kdri Kristinsson., Hafrun Fridriksddttir., et al., Dexamethasone - 
Cyclodextrin- Polymer Co-Complexes in Aqueous Eye Drops.,   Investigative 
Ophthalmology & Visual Science, May 1996, Vol. 37 (6) 
30. Robert J. Noecker., MD; Lisa A. Herrygers., MD., Effect Of Preservatives in 
Chronic Ocular Therapy.,   Clinical & Surgical Journal of Ophthalmology 
31. Angela M. de Campos., Yolanda Diebold., et al.,  Chitosan Nanoparticles As 
New Ocular Drug Delivery Systems: In Vitro Stability,                              
In Vivo  Fate, And Cellular Toxicity.,   Pharmaceutical Research, Vol. 21, No. 5, 
May 2004 
32. Hakan eroglu., H. Süheyla KAS.,  et al.,  Preparation of Bovine Serum 
Albumin Microspheres Containing Dexamethasone Sodium Phosphate and 
the in Vitro Evaluation.,    Turk J Med Sci 30 (2000) 125–128  
33. Izabela Galeska., Tae-Kyoung Kim.,  et al.,  Controlled Release of 
Dexamethasone From PLGA Microspheres Embedded Within Polyacid-
Containing PVA Hydrogels.,  The AAPS Journal 2005; 7 (1) Article 22 
(http://www.aapsj.org). 
 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
112
 
 
34. Xiuling Lu., Melissa D. Howard., et al., Nanoparticles Containing  Anti-
Inflammatory Agents as Chemotherapy Adjuvants: Optimization and In 
Vitro Characterization.,   The AAPS Journal, Vol. 10, No. 1, March 2008   
35. Qing-yu Xiang., Min-ting Wang., et al., Lung-Targeting Delivery of 
Dexamethasone Acetate Loaded Solid Lipid Nanoparticles., Arch Pharm Res 
Vol 30(4), 519-525, 2007 http://apr.psk.or.kr 
36. L.W. Norton., H.E. Koschwanez.,  et al.,  Vascular Endothelial Growth Factor 
and Dexamethasone Release from Nonfouling Sensor Coatings affect the 
Foreign Body Response., Journal of Biomedical Materials DOI: 
10.1002/jbm.a.31088 
37. Masayo Higashiyama., Katsuhiro Inada., et al., Improvement of the Ocular 
Bioavailability of Timolol By Sorbic Acid   International Journal of 
Pharmaceutics 272 (2004) 91–98 
38. Sanjay., Bidkar Devendra Jain., et al.,  Formulation Development and 
Evaluation of Fluconazole Gel in Various Polymer Basesformulation 
Development and Evaluation of Fluconazole Gel in Various Polymer Bases.,    
Asian journl of Pharm Vol 1, Iss 1, April - June, 2007 
39. Jayanta Kumar Pandit et al ., In Vitro and In Vivo Evaluation of the Gelrite® 
Gellan Gum-Based Ocular Delivery System for Indomethacin.,  Acta Pharm. 
53 (2003) 251–261 
 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
113
 
 
40. Maria J., Alonso Angela M., De Campos., et al., Chitosan Nanoparticles: a new 
vehicle for the Improvement of the Delivery of Drugs to the Ocular Surface. 
Application to Cyclosporin-A.,   International Journal of  Pharmaceutics 224 
(2001) 159–168 
41. Sveinn Hákon Hardarson., Hákon Hrafn Sigurdsson., et al., Ocular Powder: Dry 
Topical Formulations of Timolol are Well Tolerated in Rabbits   Journal of 
ocular pharmacology and therapeutics Volume 22 (5) 2006 
42. Chrystele Le Bourlais., et al., Ophthalmic Drug Delivery Systems Recent 
Advances  Progress in Retinal and Eye Research Vol.17 (1) 33-58, 1998 
43. Annick Ludwig., The Use of Mucoadhesive Polymers in Ocular Drug Delivery   
Advanced Drug Delivery Reviews 57 (2005) 1595– 1639 
44. Masayo Higashiyama., Tetsuya Tajika., et al., Improvement of the Ocular 
Bioavailability of Carteolol By Ion Pair. Journal of Ocular Pharmacology and 
Therapeutics Volume 229(5) 2006. 
45. Herbert e. Kaufman., Emily d. Varnell., et al., Efficacy of a Helicase-Primase 
Inhibitor in Animal Models of Ocular Herpes Simplex Virus Type 1 Infection 
Journal of Ocular Pharmacology and Therapeutics Volume 24, Number 1, 2008 
46. Kamran Hosseini., Dani Matsushima., et al.,  Pharmacokinetic Study of 
Dexamethasone Disodium Phosphate Using Intravitreal, Subconjunctival, 
and Intravenous Delivery Routes in Rabbits   Journal of Ocular Pharmacology 
and Therapeutics, Vol 24(3) june 2008, 301-308 
Dexamethasone Sodium Phosphate Nanoparticles For Post Cataract Treatment 
 
  
  
114
 
 
47. Neeraj Kumar., Sweta Modi., et al., Copolymers of Pharmaceutical Grade 
Lactic Acid and Sebacic Acid: Drug Release Behavior and Biocompatibility. 
European Journal of Pharmaceutics and Biopharmaceutics, Vol 64 (2006), 277-
286. 
48. British National Formulary -49. March 2005, Chapter 11.4.1, 524-525 
49. Boris Y. Shekunov., Chattopadhyay., et al., Particle Size Analysis in 
Pharmaceutics: Principles, Methods and Applications. Pharmaceutical 
research Vol 24 (2) Feb 2007, 203-227. 
50. Leyang Zhang., Yong Hu., et al., Camptothecin derivative- loaded 
poly(caprolactone-co-lactide)-b-PEG-b-poly (caprolactone-co-lactide) 
nanoparticles and their biodistribution in mice. Journal of controlled release 
96: 135-148   
51. K. Shen G Lim., Sanjeewa. S., et al., Accuracy of Intraocular Pressure 
Measurements in New Zealand White Rabbits, Investigative ophthalmology 
and visual science. Vol 46; 2005; 2419-2423. 
52. Abdullahi Elsa., et al., Ketamine anesthesia following premedication of rabbits 
with vitamin C, Journal of Vet. Science vol 6 (3), 2005, 239-241. 
 
 
 
